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Chapter 1
Introduction
1.1 Background
In recent years, interest in targeted therapies has increased greatly. Knowledge of the
molecular basis of a disease and the treatment's mode of action often allows to specify
a subset of patients based on genetic or molecular biomarkers who are expected to have
an increased beneﬁt from the treatment. Especially, in oncology, targeted therapies are
developed more and more frequently (see, e.g., Pérez-Herrero and Fernández-Medarde,
2015). An example is the treatment of breast cancer with trastuzumab, for which eﬃcacy
was only shown for patients with HER2-positive tumors. An overexpression of the human
epidermal growth factor receptor-2 (HER2) is known to play an important role in the
development of breast cancer. Trastuzumab binds to the HER2 receptor and inhibits
the growth of HER2-overexpressing breast cancer cells (Baselga, 2001). Another example
from the ﬁeld of pneumonology, which is considered later in this thesis, is the treatment
of lebrikizumab for patients with asthma that is more eﬃcient in speciﬁc subgroups
(Corren et al., 2011).
If the beneﬁt of a treatment depends on individual characteristics of a patient, study
designs allowing to demonstrate eﬃcacy in particular subgroups of the overall patient
population become more important. In case of conjecturing a higher treatment eﬀect
in a speciﬁc subgroup, the traditional approach consists of two separate clinical trials.
In a phase II study, patients from the total population are enrolled, and estimated
treatment eﬀects in both the subgroup and the total population are used to select the
target population with the most promising beneﬁt. In a subsequent phase III trial, only
patients from the selected target population are recruited and its treatment eﬀect is
assessed based on the data obtained from the phase III study. However, this approach is
very time consuming and resource intensive since selection of the target population and
assessment of eﬃcacy is divided into two separate trials.
1
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As a less time consuming and more eﬃcient approach, so-called adaptive enrichment
designs have been proposed combining both selection of the patient population and
conﬁrmatory assessment of the treatment eﬀect in one trial (see, e.g., Wang et al., 2007;
Jenkins et al., 2011). Thereby, patients from the total population are enrolled in the ﬁrst
stage of the study. Then, an interim analysis is conducted to select the target population
with the most promising treatment beneﬁt. Depending on the selected target population,
patients from the total population are enrolled in the second stage, or recruitment in the
second stage is restricted to patients from the subgroup only. In the ﬁnal analysis, data
from both stages are combined for the investigation of eﬃcacy.
1.2 Aim and Structure of the Thesis
In recent years, various statistical methods for adaptive enrichment designs have been
developed and proposed in the literature, e.g., diﬀerent rules for the selection of the
target population and several methodologies related to the control of the type I error
rate (see, e.g., Wang et al., 2007; Brannath et al., 2009; Jenkins et al., 2011; Friede
et al., 2012). However, the choice of the interim analysis timing has not been very well
investigated yet. One possible ad hoc strategy would be to conduct the interim analysis
after half of the patients are enrolled. However, this is rather a rule of thumb and is not
based on any statistical considerations. Moreover, the timing of the interim analysis in
an adaptive enrichment design has a substantial impact on the composition of the study
populations if the subgroup is chosen in the interim analysis. If the subgroup is selected
as target population in an early interim analysis, the study contains overall substantially
more patients from the subgroup as compared to the case when the subgroup is selected
in a late interim analysis. A schematic representation of an early and a late interim
analysis (or, in other words, a small and, respectively, a large sample size in the ﬁrst
stage) is shown in Figure 1.1.
Based on heuristic considerations, it is clear that a very early conduct of the interim
analysis might be inappropriate since selection of the target population is then based
on a small data set and the probability of selecting the wrong population is rather high
which may have severe consequences. For example, if the subgroup is selected as target
population but there is also a relevant treatment eﬀect in the complementary group, the
treatment may be denied to this patient group. Also, if the total population is erroneously
selected but there is only a relevant eﬀect in the subgroup, the study might fail to prove
eﬃcacy, which is especially likely if the prevalence of the subgroup is small. On the
other hand, a very late interim analysis does not seem to be sensible either. In case the
subgroup is selected at a late interim analysis, it is no longer possible to substantially
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Figure 1.1: Schematic illustration of an early and a late interim analysis using an
adaptive enrichment design with ﬁxed overall sample size. The total patient population
is denoted by G0 and the subgroup by G+.
enrich the study population with patients from the subgroup. Nevertheless, it is not
clear if the interim analysis timing after the enrollment of half the patients is uniformly
the best choice.
The aim of this thesis is to investigate the choice of the interim analysis timing in
adaptive enrichment designs for the situation of a normally distributed outcome. In the
ﬁrst part, a design with ﬁxed overall sample size speciﬁed at the beginning of the trial
is considered. Here, the impact of the timing on the power of the study is investigated
for various eﬀect sizes, prevalences of the subgroup, and diﬀerent selection rules. The
aim of these investigations is to assess to what extent the timing inﬂuences the power of
the study in general, and which timings are favorable or unfavorable with regard to the
power of the trial.
In the second part of the thesis, scenarios are considered in which the overall sample
size is not ﬁxed. Instead, the sample size of the second stage is recalculated based on
the treatment eﬀect observed in the interim analysis. In this case, characteristics of
sample size distribution are compared for diﬀerent interim analysis timings. Here, it is
investigated to what extent the timing inﬂuences the distribution of the sample size and
which timing is appropriate regarding the average sample size for scenarios with diﬀerent
eﬀect sizes, prevalences of the subgroup, and selection rules.
Overall, the thesis is structured as follows: In Chapter 2, the theoretical framework on
adaptive enrichment designs is given. Chapter 3 gives the basic notation and describes
the considered design together with the two diﬀerent classes of selection rules for se-
lecting the target population. In Chapter 4, the choice of the interim analysis timing
is investigated if the overall sample size is ﬁxed. As an alternative, in Chapter 5, the
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impact of the interim analysis timing is examined for an adaptive enrichment design with
sample size reassessment. Chapter 6 concludes with a discussion, and a summary of the
thesis is given in Chapter 7.
Results concerning the adaptive enrichment design with ﬁxed overall sample size were
already published in Benner and Kieser (2018). All simulations were performed using R,
version 3.5.0 (R Core Team, 2018), and corresponding program code is provided in the
Appendix.
Chapter 2
Theoretical Framework
Beside the use of adaptive enrichment designs, adaptive designs in general are very
popular as they allow ﬂexible modiﬁcations of the design in an ongoing study under
control of the type I error rate.
An overview of the development of methodologies for adaptive designs is given by Bauer
et al. (2016). After the ﬁrst seminal publications of Bauer (1989) and Bauer and Köhne
(1994), various methods were developed. For example, strategies were proposed to assure
control of the type I error rate within an adaptive design. In general, two diﬀerent ap-
proaches exist. The ﬁrst strategy is based on the combination of p-values or test statistics
obtained from the two stages of the study. Commonly used combination methods are
Fisher's combination test (Bauer, 1989; Bauer and Köhne, 1994), where the product of
both p-values is compared to a critical value, or the weighted inverse normal combination
function (Lehmacher and Wassmer, 1999), where statistics from both stages (p-values or
test statistics) are weighted and combined. The latter method is used in this work and
is described in detail in the subsequent chapter. The second commonly used strategy to
assure control of the type I error rate was proposed by Proschan and Hunsberger (1995)
and is based on the conditional error function.
One important application of adaptive designs is the reassessment of sample size in the
interim analysis. Since assumed treatment eﬀects and standard deviations are often
vague in the planning phase for calculating the sample size, the data observed in the
ﬁrst stage can be used to adjust the sample size of the subsequent stage. For example,
the sample size can be adjusted upwards if the observed eﬀect size in the interim anal-
ysis is smaller than expected, and downwards if the eﬀect size is higher than expected.
A commonly used method for sample size reassessment is based on conditional power
arguments (Proschan and Hunsberger, 1995), and is applied in this work for sample size
recalculation using an adaptive enrichment design.
However, not only the sample size can be modiﬁed using an adaptive design. The
5
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ﬂexibility of adaptive designs ﬁnd a variety of applications. For example, EMA and
FDA mention in their guidelines (European Medicines Agency, 2007; Food and Drug
Administration, 2018) the adaptation of sample size, the allocation ratio, change of
endpoints, selection of the most promising treatments, and selection of subgroups. Also
a stop for futility or eﬃcacy is possible if observed eﬀects in the interim analysis provide
already suﬃcient information. In this case, the trial is stopped early after the interim
analysis either with acceptance or rejection of the null hypothesis, and the sample size
can be reduced.
One useful application in the ﬁeld of stratiﬁed medicine is the adaptive enrichment design,
which oﬀers the possibility to select the target population in the interim analysis and
accordingly, adapt the population from which patients in the second stage are enrolled.
While in general it would be possible to consider multiple subgroups (see, e.g., Wassmer
and Dragalin, 2015), this work solely considers the situation of a single subgroup G+ in
which a higher treatment eﬀect is assumed compared to the total population G0.
The basic process of a study using an adaptive enrichment design is as follows: Patients
from the total population G0 are enrolled in the ﬁrst stage of the study. After completion
of the ﬁrst stage, based on the data observed so far, an interim analysis is conducted,
where the target population (G+ or G0) with the most promising treatment eﬀect is
selected. Depending on the selected target population in the interim analysis, patients
from the total population are enrolled in the second stage, or recruitment is restricted to
patients from the subgroup only, which is referred to as enrichment. In the ﬁnal analysis,
data from both stages are combined for the investigation of eﬃcacy. In this way, the
selection of the target population and the test for eﬃcacy is combined in a single trial
consisting of two stages, which is less resource intensive and less time consuming than
conducting two separate trials.
In recent years, several approaches and methodologies for applying adaptive enrichment
designs were proposed. To control the type I error rate, most approaches make use of
combination tests as, for example, described in Wang et al. (2007), Wang et al. (2009) or
Jenkins et al. (2011) but also applying the conditional error function approach is possible
as implemented by Friede et al. (2012). The adjustment for multiplicity arising from the
two considered populations can be handled using commonly methods such as Bonferroni
correction or the closure principle.
Especially, there are various ways to deﬁne the rule for selecting the target population.
Besides Bayesian decision tools, as described in Brannath et al. (2009), several simple
selection rules were proposed based on the diﬀerence between eﬀect sizes or comparing
eﬀect sizes to a pre-speciﬁed threshold value. In this thesis, two diﬀerent classes are
considered, which are both based on the estimated treatment eﬀects in G0 and G+
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calculated with data observed in the ﬁrst stage. The ﬁrst selection rule is based on the
diﬀerence between standardized eﬀect estimates and is a variant of the -selection rule
proposed by Kelly et al. (2005) and Friede and Stallard (2008) in the context of treatment
selection. If the estimated eﬀect in the subgroup is larger than the eﬀect in the total
population by a pre-speciﬁed amount, only the subgroup is selected; otherwise, patients
from the total population are enrolled in the second stage of the trial. The second
selection rule, that is considered in this thesis, is based on absolute eﬀect estimates and
was originally proposed by Jenkins et al. (2011) for time-to-event endpoints. Using this
selection rule, the estimated eﬀect sizes in both populations are compared to pre-speciﬁed
threshold values. Using this selection rule, either a single population is selected, both
populations are selected, or the trial is stopped early for futility.
It should be noted that most adaptive enrichment designs are based on the assumption
of an increased treatment beneﬁt in an already pre-deﬁned subgroup. This is usually the
case if the biomarker deﬁning the subgroup has already been validated in prior trials.
If there is a high uncertainty regarding the actual tailoring of the subgroup, designs
which allow to deﬁne the subgroup based on data from the current trial might be more
advisable. Two examples are the design by Renfro et al. (2014), where a biomarker cutoﬀ
is determined at interim, and the design by Chen et al. (2016), where part of the trial
data is used to potentially modify design elements such as the investigated subgroup. In
this thesis, however, the situation of a pre-deﬁned subgroup which will not be subject to
any data-driven alterations is considered.
Chapter 3
Methods
3.1 Design and Notation
In this thesis, a parallel-group clinical trial with an adaptive two-stage enrichment design
is considered, where a higher treatment beneﬁt is expected in a prespeciﬁed subpopula-
tion. The total population is denoted by G0 and the subgroup with the higher expected
beneﬁt by G+ ⊂ G0. The complement is indicated by G−, and the prevalence of G+
is given by p. It is assumed that the prevalence in the total patient population and
the study population is equal, and that the prevalence in the study population is ﬁxed
and not variable. Furthermore, in both populations, equal allocation to both treatment
groups is assumed. The overall sample size per treatment group is denoted by n, the
sample size in stage I is given by nI and in stage II by nII . The number of patients per
group from the subgroup in the ﬁrst stage is given by nI+ = pn
I . In the second stage,
the number of patients from the subgroup is
nII+ =
nII if G+ is selectedpnII if G0 is selected.
Throughout this thesis, a normally distributed outcome is considered. Therefore, the
independent random samples for treatment and control group
XT+i ∼ N (µT+, σ+), i = 1, ..., nI+ + nII+
XC+j ∼ N (µC+, σ+), j = 1, ..., nI+ + nII+
are assumed for the biomarker positive subgroup, where µT+ and µC+ are the means in
the treatment and control group in G+, and σ+ is the common known standard deviation.
8
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Similarly, the independent random samples
XT−k ∼ N (µT−, σ−), k = 1, ..., n− nI+ − nII+
XC−l ∼ N (µC−, σ−), l = 1, ..., n− nI+ − nII+
are assumed for the biomarker negative subgroup, where µT− and µC− are the means
in the treatment and control group in G−, and σ− is the common known standard
deviation. The standardized treatment eﬀects are deﬁned as ∆+ = (µT+ − µC+)/σ+ in
G+ and ∆− = (µT− − µC−)/σ− in G−. Thereby, the treatment eﬀect in G0 is given
by ∆0 = p∆+ + (1 − p)∆−. Estimated treatment eﬀects from the ﬁrst-stage data in
population G0 and G+ are denoted by ∆̂0 and ∆̂+, respectively, and are calculated by
∆̂+ =
1
σ+nI+
 nI+∑
i=1
XT+i −
nI+∑
j=1
XC+j

∆̂0 = p∆̂+ +
1
σ−nI
(1−p)nI∑
k=1
XT−k −
(1−p)nI∑
l=1
XC−l

using the maximum likelihood estimator. In the second stage, estimated treatment eﬀects
are denoted by ∆̂II0 for G0 and ∆̂
II
+ for G+, and are calculated analogously:
∆̂II+ =
1
σ+nII+
nI++nII+∑
i=nI++1
XT+i −
nI++n
II
+∑
j=nI++1
XC+j

∆̂II0 = p∆̂
II
+ +
1
σ−nII
 n−nI+−nII+∑
k=(1−p)nI+1
XT−k −
n−nI+−nII+∑
l=(1−p)nI+1
XC−l
 .
However, ∆̂II0 only exists if G0 is selected as target population.
Furthermore, for the two considered populations, diﬀerent hypotheses are formulated.
For convenience, it is assumed that higher values for the outcome are related to favourable
results. Hence, the following one-sided hypotheses are considered:
H
(0)
0 : ∆0 ≤ 0 versus H(0)1 : ∆0 > 0
for the eﬀect in the total population, and
H
(+)
0 : ∆+ ≤ 0 versus H(+)1 : ∆+ > 0
for the eﬀect in the subgroup. To cover the aim of rejecting at least one of the hypotheses
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H
(0)
0 or H
(+)
0 , the following hypotheses are considered:
H
(0+)
0 : ∆0 ≤ 0 ∩ ∆+ ≤ 0 versus H(0+)1 : ∆0 > 0 ∪ ∆+ > 0.
The timing of the interim analysis t is deﬁned by the ratio of number of patients in
the ﬁrst stage and the overall sample size, i.e. t = nI/n, yielding possible values for t
between 0 and 1.
3.2 Selection Rules
In the following, two diﬀerent classes of selection rules are described, that are considered
in this thesis. For a detailed assessment of the statistical properties of the two classes
of rules and their performance in trials with subgroup selection, see, e.g. Krisam and
Kieser (2014).
3.2.1 Selection Rule Based on Estimated Eﬀect Diﬀerences
The ﬁrst selection rule is a variant of the -selection rule proposed by Kelly et al. (2005)
and Friede and Stallard (2008) in the context of treatment selection. In the originally
proposed approach, the most promising treatments are selected from a pool of several
diﬀerent treatments, and the predeﬁned diﬀerence is related to the treatment showing
the largest eﬀect in the interim analysis.
This selection rule is transferred to the situation of an adaptive enrichment design which
is based on the design described by Wang et al. (2007), where a higher treatment beneﬁt
is expected in a prespeciﬁed subpopulation. In the interim analysis it is decided if the
total population or the subpopulation is considered as the target population deﬁning
which patients are recruited in the second stage of the trial and which hypothesis is
tested in the ﬁnal analysis.
The selection rule for selecting the target population considered in this thesis is based
on the diﬀerence between estimated eﬀect sizes from the interim analysis in the total
patient population and the subgroup, i.e. ∆̂+ − ∆̂0. This diﬀerence is compared to a
predeﬁned constant c. If ∆̂+− ∆̂0 ≤ c, patients from G0 are enrolled in the second stage
and H
(0)
0 is tested at the end of the trial. If ∆̂+ − ∆̂0 > c, patients from the subgroup
only are enrolled in the second stage and the null hypothesis H
(+)
0 is tested in the ﬁnal
analysis. A schematic illustration of the application of this selection rule is shown in
Figure 3.1.
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Stage I
Interim Analysis
Stage II
Final Analysis
Enroll patients from G0
Calculate ∆̂+, ∆̂0
Is ∆̂+ − ∆̂0 ≤ c?
Select G0 as tar-
get population
Select G+ as tar-
get population
Enroll patients from G0
Test H
(0)
0
Enroll patients from G+
Test H
(+)
0
yes no
Figure 3.1: Flow chart of an adaptive enrichment design using the selection rule based
on estimated eﬀect diﬀerences
It should be noted that it also would be possible to test both hypotheses in the ﬁnal
analysis. If G0 is selected and H
(0)
0 is tested, data from both stages can be used to
test also H
(+)
0 . If G+ is selected, only data from the ﬁrst stage can be used to test H
(0)
0 .
However, investigations in this thesis are restricted to the case where only the hypothesis
related to the selected population is tested since this hypothesis should be of primary
interest. Nevertheless, although only one hypothesis is tested in the ﬁnal analysis, the
α-level has to be adjusted.
In general, this simple class of selection rules has the disadvantage that the absolute
eﬀect sizes within the two target populations are irrelevant. Exactly one hypothesis is
tested in the ﬁnal analysis, thus ignoring whether the observed eﬀects in the interim
analysis are both very high (thus justifying to test both hypotheses in the ﬁnal analysis)
or both very small (thus indicating that there is no treatment eﬀect in either of the pop-
ulations, justifying an early stop for futility). A selection rule overcoming this drawback
is presented in the following subsection where the absolute eﬀect sizes are considered.
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3.2.2 Selection Rule Based on Absolute Eﬀect Estimates
The second class of selection rules is based on absolute eﬀect estimates. Using this
selection rule, two threshold values c0 and c+ have to be speciﬁed for the continuation or
termination of the total population and the subgroup, respectively. This approach was
originally proposed by Jenkins et al. (2011) for time-to-event data, where the hazard
ratio estimates were compared to predeﬁned target values. In contrast to the selection
rule based on the estimated eﬀect diﬀerences where either H
(0)
0 or H
(+)
0 is tested, the
selection rule proposed by Jenkins et al. (2011) additionally includes the option to stop
for futility as well as the option to test both hypotheses H
(0)
0 and H
(+)
0 at the end of the
trial. The latter is also referred to as the co-primary option.
Stage I
Interim Analysis
Stage II
Final Analysis
Enroll patients from G0
Calculate ∆̂+, ∆̂0
Is ∆̂0 > c0?
Is ∆̂+ > c+? Is ∆̂+ > c+?
Select G0 and G+
as target population
Select G0 as tar-
get population
Select G+ as tar-
get population
Enroll patients
from G0
Enroll patients
from G0
Enroll patients
from G+
Stop for
futility
Test H
(0)
0 and H
(+)
0 Test H
(0)
0 Test H
(+)
0
yes no
yes no yes
no
Figure 3.2: Flow chart of an adaptive enrichment design using the selection rule based
on absolute eﬀect estimates
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The overall procedure that is here merely adapted to normally distributed outcomes is
shown in Figure 3.2. Basically, estimated treatment eﬀects ∆̂0 and ∆̂+ are calculated
in the interim analysis and are compared to the predeﬁned threshold values c0 and
c+, respectively. If only one eﬀect exceeds the threshold, the respective population is
selected as target population and the associated hypothesis is tested in the ﬁnal analysis.
If both estimated eﬀects are larger than the respective threshold values, i.e. ∆̂0 > c0
and ∆̂+ > c+ and hence, the treatment is promising for both populations, patients from
G0 are enrolled in the second stage and both hypotheses H
(0)
0 and H
(+)
0 are tested in the
ﬁnal analysis. If both eﬀect estimates are below the chosen threshold values, i.e. ∆̂0 ≤ c0
and ∆̂+ ≤ c+, no second stage is performed and the study is stopped with prematurely
accepting both null hypotheses. This option has the advantage that it prevents further
patients receiving an ineﬀective therapy and moreover, resources are saved.
Furthermore, it should be noted that it would also be possible to base the selection of the
target population in the interim analysis on a diﬀerent endpoint than the endpoint used in
the ﬁnal analysis. In the originally proposed decision framework by Jenkins et al. (2011)
for time-to-event endpoints, a surrogate endpoint for selecting the target population was
used, and the actual primary endpoint was considered in the ﬁnal analysis. This might
especially be useful for time-to-event endpoints where the observation period is long until
an event occurs. In this thesis, where a normally distributed endpoint is considered, the
endpoint used for subgroup selection is also the endpoint used for hypothesis testing at
the end of the trial.
3.3 Testing Procedures
In the following, the testing procedure is presented for the previously described adaptive
enrichment design for both selection rules. Diﬀerent methods exist to handle the multi-
stage structure of an adaptive design under control of the type I error rate. In this
work, the inverse normal combination method (Lehmacher and Wassmer, 1999) is used.
Within this approach, single z-test statistics are calculated for each stage separately and
are combined to one statistic in the ﬁnal analysis. It should be noted that the inverse
normal combination method can also be used if z-tests are not appropriate, for example,
if the standard deviation is not known, which is usually the case in clinical trials. In this
case, the fact is utilized that the transformation Φ−1(1−p) of any uniformly distributed
p-value p is standard normal. Here, Φ−1 denotes the inverse of the cumulative standard
normal distribution function. However, for sake of simplicity, in this thesis, known
standard deviations are assumed and the use of a z-test is considered. In this case, the
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single test statistics in the ﬁrst stage are given by
ZI0 = ∆̂0
√
nI
2
(3.3.1)
for G0 and by
ZI+ = ∆̂+
√
nI+
2
(3.3.2)
for G+. In the second stage, the test statistics depend on the selected population. The
test statistic for testing H
(0)
0 , which is only available if G0 is selected, is given by
ZII0 = ∆̂
II
0
√
nII
2
. (3.3.3)
The test statistic for G+ is given by
ZII+ = ∆̂
II
+
√
nII+
2
. (3.3.4)
Using the inverse normal combination method, test statistics from both stages are com-
bined. Weights w1 and w2 have to be pre-speciﬁed so that the sum of squared weights is
equal to 1 (w21 + w
2
2 = 1). One reasonable approach is to choose the weights so that the
resulting test statistic is equal to the statistic when no interim analysis were performed.
This is achieved for weights chosen according to the information time, which leads to
the overall test statistic
Z0 =
√
tZI0 +
√
1− tZII0 (3.3.5)
for testing H
(0)
0 (only if the total population is selected). The weights w1 and w2 in the
statistic for testing H
(+)
0
Z+ = w1Z
I
+ + w2Z
II
+ , (3.3.6)
depend on the selected population. If G0 is selected, the weights are selected as above
using w1 =
√
t and w2 =
√
1− t. When selecting the subgroup only, the sample size in
the second stage for G+ is increased, which is also represented by the weights given by
w1 =
√
tp
tp+1−t and w2 =
√
1−t
tp+1−t .
Furthermore, an adjustment for multiplicity has to be conducted since two hypotheses
are considered. Even if only one hypothesis is tested in the ﬁnal analysis, the tested
hypothesis was not selected in the planning phase and a multiplicity adjustment is nec-
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essary to control the familywise error rate.
Bonferroni correction
A simple method to adjust for multiplicity is the Bonferroni correction, where each
hypothesis is tested at level α/2 to assure that the familywise error rate does not exceed
α. If a one-sided signiﬁcance level of α/2 is used, H
(+)
0 is rejected if Z+ > z1−α/4 for the
case G+ is selected, where z1−α/4 gives the (1− α/4)-quantile of the standard normal
distribution. In case G0 is selected, H
(0)
0 is rejected if Z0 > z1−α/4. If both populations
are selected as target population, which is possible using the selection rule based on
absolute eﬀect estimates, both hypotheses are independently tested at level α/4.
However, this easily applicable adjustment method has the disadvantage of being very
conservative, especially for positively correlated test statistics.
Closure Principle
A less conservative approach is to make use of the closure principle (Marcus et al., 1976),
which was also applied in the design proposed by Jenkins et al. (2011). Following this
method, the single hypothesis (H
(+)
0 orH
(0)
0 ) can be rejected if the intersection hypothesis
H
(0+)
0 and the respective single hypothesis is rejected at level α (or α/2 for a one-sided
signiﬁcance level). The intersection hypothesis itself can be tested applying the Simes'
procedure (Simes, 1986), which controls the familywise error rate for positively correlated
bivariate normally distributed test statistics (Sarkar and Chang, 1997).
If only one hypothesis is tested in the ﬁnal analysis, which is always the case using the
selection rule based on estimated eﬀect diﬀerences as described above, Simes' procedure
is applied only on the data of the ﬁrst stage. Thereafter, for testing H
(0+)
0 , the test
statistic resulting from the Simes' procedure in the ﬁrst stage is combined with the test
statistic of the selected population from the second stage.
For testing H
(0+)
0 , Simes' procedure controlling the familiy wise error rate α/2 for one-
sided hypotheses is as follows: P-values related to the test of H
(0)
0 and H
(+)
0 are sorted
according to size, and H
(0+)
0 can be rejected if the smaller p-value is less than α/4 or the
larger p-value is less than α/2. Since a test statistic is needed that is combined with the
test statistic from the second stage using the inverse normal combination test, Simes'
procedure is expressed as
ZI0+ = Φ
−1 (1−min[ 2− 2Φ(max(ZI0 , ZI+)), 1− Φ(min(ZI0 , ZI+)) ]) , (3.3.7)
for stage I, where Φ denotes the standard normal distribution function. The combination
of stage I and II applied to test the intersection hypothesis using the inverse normal
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method is then given by
Z
(0)
0+ =
√
tZI0+ +
√
1− tZII0
if G0 is selected and
Z
(+)
0+ =
√
tZI0+ +
√
1− tZII+
in case G+ is selected. Finally, H
(0+)
0 is rejected if Z
(0)
0+ > z1−α/2 or Z
(0)
0+ > z1−α/2
depending on whether G0 or G+ is selected as target population.
In case that both populations are selected in the interim analysis, which is an option
using the selection rule based on absolute eﬀect estimates, both hypotheses H
(+)
0 and
H
(0)
0 are to be tested. The procedure using the closure principle for this case is described
in the following: The intersection hypothesis can be tested using
Z ′0+ =
√
tZI0+ +
√
1− tZII0+,
where ZI0+ is deﬁned in formula (3.3.7) and Z
II
0+ is given by
ZII0+ = Φ
−1 (1−min[ 2− 2Φ(max(ZII0 , ZII+ )), 1− Φ(min(ZII0 , ZII+ )) ]) .
Thus, H
(0+)
0 is rejected if Z
′
0+ > z1−α/2.
To summarize, when applying the closure principle with the use of Simes' procedure for
testing the intersection hypothesis H
(0+)
0 , the testing procedure is as follows:
Case 1: G0 is selected as target population:
 Reject H
(0)
0 if Z0 > z1−α/2 and Z
(0)
0+ > z1−α/2
Case 2: G+ is selected as target population:
 Reject H
(+)
0 if Z+ > z1−α/2 and Z
(+)
0+ > z1−α/2
Case 3: G0 and G+ are selected as target population:
 Reject H
(0)
0 if Z0 > z1−α/2 and Z
′
0+ > z1−α/2
 Reject H
(+)
0 if Z+ > z1−α/2 and Z
′
0+ > z1−α/2
It should be noted that the third case is only possible using the selection rule based on
absolute eﬀect estimates. Moreover, using this selection rule, a further case is possible,
namely the stop for futility, where all null hypotheses are prematurely accepted.
Chapter 4
Design with Fixed Sample Size
In this chapter, the timing of the interim analysis is investigated using an adaptive
enrichment design with ﬁxed overall sample size speciﬁed in the planning phase of the
study. This means that the decision in the interim analysis only determines whether
patients enrolled in the second stage originate from the total population or the subgroup,
but the overall sample size is not adjusted. For this design, power characteristics are
investigated for diﬀerent interim analysis timings. The power considered here is deﬁned
as the probability to reject either H
(0)
0 or H
(+)
0 .
In Section 4.1, the power function is presented as a mathematical expression for the
selection rule based on estimated eﬀect diﬀerences. Since this could not be converted
into a closed form, simulation studies were used to investigate power characteristics.
Results of simulation studies are presented in Section 4.2 for the two diﬀerent classes of
selection rules (based on estimated eﬀect diﬀerences, and respectively, based on absolute
eﬀect estimates). The main results of the simulation studies presented in this section are
taken from Benner and Kieser (2018). In Section 4.3, the impact of the interim analysis
on power is investigated for parameters obtained from a real clinical trial examining a
therapy for patients with asthma. The chapter closes with a summary in Section 4.4.
4.1 Analytical Derivation of Power Function
In the following, the power function is derived for the selection rule based on estimated
eﬀect diﬀerences. Due to matters of simplicity, the Bonferroni correction is applied. For
solving integrals in the expression of the power function, Mathematica 11.3 (Wolfram
Reseach, Inc., 2018) was used.
The aim is to specify the power as a function of the eﬀect sizes ∆0 and ∆+, t, p and n.
Hence, the sample sizes for diﬀerent groups and stages are expressed as a function of n,
t and p in the following way: nI = tn and nI+ = tnp for the sample sizes in stage I, and
17
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nII = (1−t)n for the sample size in stage II. Without loss of generality, it is assumed that
σ+ = σ− = 1. Theoretically, the derivative with respect to t of this power function could
deliver the timing with the maximal power. However, the integral cannot be solved using
elementary functions. Some integrals can be expressed with the help of the error function
Erf(x) = 1√
pi
∫ x
−x e
−t2 and the imaginary error function Erfi(x) = −iErf(ix), for other
integrals, no results could be found in terms of standard mathematical functions. Hence,
a power maximum cannot be given analytically. Nevertheless, an analytical derivation
of the power function is provided in the following. Results were conﬁrmed comparing
the last transformed expression calculated using numerical integration with results from
simulation studies.
For calculating the power function, the joint probability density function of ∆̂0 and ∆̂+
is used (see Krisam and Kieser (2014) for derivation), which is given by
(∆̂0, ∆̂+) ∼ N
(
(∆0,∆+),
(
2/(tn) 2/(tn)
2/(tn) 2/(ptn)
))
as well as the distribution of the eﬀect in the second stage, that is
∆̂II0 ∼ N
(
∆0,
2
(1− t)n
)
if G0 is selected, and
∆̂II+ ∼ N
(
∆+,
2
(1− t)n
)
if G+ is selected. It can easily be seen that the correlation between ∆̂0 and ∆̂+ is
Corr(∆̂0, ∆̂+) =
√
p. The joint density function of ∆̂0 and ∆̂+ is denoted by f∆̂0,∆̂+ ,
and the densities for the eﬀects in the second stage are denoted by f∆̂II0
and f∆̂II+
.
The probability to reject either H
(0)
0 or H
(+)
0 is given by the sum of the two probabilities
Pr(select G0 ∩ reject H(0)0 ) + Pr(select G+ ∩ reject H(+)0 ).
The ﬁrst probability referring to the rejection of H
(0)
0 at the end of the trial is given by
Pr(reject H
(0)
0 ∩ select G0) (4.1.1)
= Pr(Z0 > z1−α/4 ∩ ∆̂0 ≥ ∆̂+ − c)
=
√
n(1− t)
8
√
pi
(
1 + Erf
{
1
2
√
ntp
1− p (c+ ∆0 −∆+)
})
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·
∞∫
δII0 =−∞
exp
{n
4
(t− 1) (∆0 − δII0 )2}
·
(
1− Erf
{
1
2
√
nt
((
z1−α/4 − (1− t)δII0
√
n
2
) √
2
t
√
n
−∆0
)})
dδII0
For the last integral, no solution could be found with Mathematica. The detailed calcu-
lation of the probability given in (4.1.1) can be found in Appendix A.
The probability for rejecting the hypothesis H
(+)
0 can be derived in a similar way (see
Appendix A for detailed derivation):
Pr(Z+ > z1−α/4 ∩ ∆̂0 < ∆̂+ − c) (4.1.2)
=
∞∫
δ+=−∞
1
8
√
npt
pi
· exp
{
−npt
4
(∆+ − δ+)2
}
·
(
1 + Erf
{ √
nt
2
√
1− p(−∆0 + p(∆+ − δ+) + δ+ − c)
})
·
(
1 + Erf
{
−
√
n(1− t)
2
(
−∆+ +
(
z1−α/4
√
2(tp+ 1− t)
n
− tpδ+
)
1
1− t
)})
dδ+
As already seen for the calculation of the ﬁrst probability, no solution for the last integral
could be found. In addition to the presented approach, other strategies were explored,
namely using the density of ∆̂− and ∆̂+ instead of f∆̂0,∆̂+ or using a diﬀerent integration
order. In any case, the term could not be transformed into a closed form.
For the selection rule based on absolute eﬀect estimates, the power function can be
formulated in a similar way. Here, the overall power is the sum of the probabilities
Pr(Z+ > z1−α/4 ∩ ∆̂0 ≤ c0 ∩ ∆̂+ > c+)
+Pr(Z0 > z1−α/4 ∩ ∆̂0 > c0 ∩ ∆̂+ ≤ c+)
+Pr
(
(Z+ > z1−α/4 ∪ Z0 > z1−α/4) ∩ ∆̂0 > c0 ∩ ∆̂+ > c+
)
.
However, also in this case, no solution for the integral can be found and calculations are
not presented.
CHAPTER 4. DESIGN WITH FIXED SAMPLE SIZE 20
4.2 Simulation Study
4.2.1 Simulation Setup
The power is simulated for diﬀerent interim analysis timings between 0.05 and 0.95 in in-
crements of 0.025. Furthermore, diﬀerent scenarios with varying eﬀect sizes, prevalences
and selection rules are considered. The standardized eﬀect in the subgroup is ﬁxed to
0.5 and the power for various ∆− is determined. Values between 0 and 0.5 for ∆− are
considered in steps of 0.05. The inﬂuence of the prevalence is investigated for p = 0.2, 0.4
and 0.7, and the one-sided signiﬁcance level α/2 = 0.025 is used. For both classes of
selection rules, diﬀerent choices of the threshold values are considered. Applying the
selection rule based on estimated eﬀect diﬀerences, scenarios are investigated for c = 0
and c = 0.2, and for the selection rule based on absolute eﬀect estimates, scenarios with
c+ = 0.1, 0.3 are considered while c0 remains constant at 0.1. To adjust for multiplicity,
Bonferroni method as well as the closure principle with Simes' procedure for testing the
intersection hypothesis was applied. Since results are very similar for both adjustment
methods, only output for the latter method is shown. In every scenario, the total sam-
ple size is determined such that a power of 80% is achieved at t = 0.5. Hence, it is
investigated whether the power for t 6= 0.5 is higher or smaller than 80% using the same
sample size. For every scenario, 1, 000, 000 study results are simulated (standard error
for a power of 50% equals 5 · 10−4).
In practice, it is not sensible to do the interim analysis extremely early or extremely
late. When conducting the interim analysis very early, the interim decision is based on
few data resulting in a high probability to select the wrong population. If the interim
analysis is performed towards the end of the trial, the probability to select the correct
population is increased but it is not possible anymore to relevantly aﬀect the composition
of the study population. For this reason, the focus is on timings between 0.3 and 0.7
and the power range in this interval is considered to specify the variability in power for
diﬀerent timings.
In addition to power considerations, the type I error rate is investigated for three diﬀer-
ent types of null distributions: the global null hypothesis is true (∆0 = 0 and ∆+ = 0),
only H
(0)
0 is true and only H
(+)
0 is true. For each null scenario, a sample size of n = 200
is chosen.
4.2.2 Selection Rule Based on Estimated Eﬀect Diﬀerences
In this section, results are presented for the selection rule based on estimated eﬀect
diﬀerences, where G+ is selected if ∆̂+ − ∆̂0 > c, and patients from G0 are enrolled in
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stage II otherwise.
Power
Figure 4.1 shows the power, deﬁned as the probability to reject H
(0)
0 or H
(+)
0 , for diﬀer-
ent interim analysis timings. Shades of color represent the amount of power; dark red
indicates a power higher than 87% and the brightest yellow characterizes a power smaller
than 73%. In Figure 4.2, the individual power curves are depicted for the rejection of
H
(0)
0 and H
(+)
0 as well as the probability to select G0 or G+ in the interim analysis as
a function of the interim analysis timing. In addition, Table 4.1 shows timings yielding
the minimal and maximal power within the interval t ∈ [0.3, 0.7].
In every scenario, the power is 80% for t = 0.5 since the sample size is determined for this
particular timing. For most of the considered simulation scenarios, the general tendency
is a power advantage for early timings. Table 4.1 reveals that the maximal power is in
most scenarios at t = 0.3 when considering timings between 0.3 and 0.7. However, the
power gain is not substantially higher compared to a timing of 0.5 as the power only
increases approximately between 1% and 3% for the considered scenarios. In contrast,
the power can get considerably smaller than 80% for late interim analysis timings in
some scenarios. This is also represented by the range of power (shown in Figure 4.1 and
Table 4.1), which is especially high for scenarios with a small prevalence (p = 0.2) and
c = 0 (see Figure 4.1a). In this case, for ∆− > 0.25, the power is highest for an interim
analysis performed at the beginning of the study and decreases for later timings. This
was to be expected since in case of high eﬀects in both populations it is rather irrelevant
in terms of power which one is selected at the beginning of the trial. However, the later
the conduct of an enrichment, the smaller sample size of the subgroup is resulting in a
smaller power. This is also apparent in Figure 4.2a for the scenario with p = 0.2 and
∆− = 0.5. The probability to select the subgroup or the total population is 0.5 and
constant for varying t. Also the probability to reject H
(0)
0 is relatively constant since
this selection has no impact on the sample size of the total population. However, if G+
is selected, the power decreases with increasing t due to the decreasing sample size of
the subgroup. For smaller ∆−, the power maximum is approximately achieved between
t = 0.3 and 0.4. In this case, selection of the subgroup is crucial to achieve a high power
as selection of the total population would decrease the power of the study due to the
small eﬀect size. Obviously, a correct interim decision (selection of the subgroup) with
a high probability is not possible at the beginning of the study. Instead, a suﬃcient
amount of data has to be available for the interim analysis. However, when conducting
the interim analysis much later where the probability for selecting the subgroup is higher,
it is no longer possible to increase the sample size of the subgroup to a substantial extent
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what is in contrast feasible when starting enrichment early. For this reason, the power
decreases clearly for later timings. For t ∈ [0.3, 0.7] the power range is given for the
considered scenarios in the column right to the graphs in Figure 4.1. For the diﬀerent
scenarios with p = 0.2 and c = 0, this power range lies between 6.8% for ∆− = 0.5 and
12.7% for ∆− = 0.
In contrast, corresponding scenarios with p = 0.4 (Figure 4.1c) and p = 0.7 (Figure
4.1e) show smaller power ranges in the time interval [0.3, 0.7]: For p = 0.4 power ranges
lie between 3.1% and 7.5% and between 1.3% and 2.8% for p = 0.7. Thus, one main
diﬀerence to scenarios with p = 0.2 is that power only slightly decreases for late interim
analysis timings. The relatively small power for late interim analysis timings in case
p = 0.2 can be explained as follows: If the subgroup is selected relatively late, the
sample size in the second stage is rather small and only 20% of the data from the ﬁrst
stage can be used. In case p = 0.7, a late selection of the subgroup does not lead to
a considerably smaller sample size since 70% of the data from the ﬁrst stage can be
included in the analysis. This characteristic is also highlighted in Figure 4.2, where
the deviation between the probability to reject H
(+)
0 and the probability to select G+ is
higher, the smaller the prevalence when considering late interim analysis timings.
In case c = 0.2 (Figure 4.1b, d and f), power ranges are smaller than for the corresponding
scenarios with c = 0. In general, use of a higher c leads to a smaller probability to
select G+, which can be seen in Figure 4.2. Hence, the power related to H
(0)
0 has
a greater contribution to the overall power which is more stable for diﬀerent interim
analysis timings. The smaller power range for higher c applies both for small and high
prevalences. For example, for p = 0.7, power is relatively constant for diﬀerent interim
analysis timings as the maximum power range is only 1.4% in the considered scenarios.
For p = 0.2, the power range lies between 1.2% and 5.2%. For rather high ∆−, the
power is highest for an interim analysis at the beginning of the study and decreases with
increasing t as displayed in the case of c = 0. In contrast, the power maximum is shifted
to later interim analysis timings for small ∆−. For example, in case ∆− = 0.1, the power
is maximal for t ≈ 0.575 using c = 0.2, and in case using c = 0 the power is maximal for
t ≈ 0.35 (see Table 4.1). One reason for the later power maximum in comparison to the
corresponding scenario with c = 0 is the higher sample size in this situation (n = 232
for c = 0.2 compared to n = 157 for c = 0.2). As a consequence, a later selection of
the subgroup still leads to a suﬃciently large sample size to reject H
(+)
0 with a high
probability.
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(a) p = 0.2, c = 0 (b) p = 0.2, c = 0.2
(c) p = 0.4, c = 0 (d) p = 0.4, c = 0.2
(e) p = 0.7, c = 0 (f) p = 0.7, c = 0.2
Figure 4.1: Probability to rejectH
(0)
0 orH
(+)
0 using the selection rule based on estimated
eﬀect diﬀerences; ∆+ = 0.5; total sample size determined to assure a power of 80% at
t = 0.5.
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(a) c = 0
(b) c = 0.2
Figure 4.2: Probability to select G+ or G0, respectively, and probability to reject
diﬀerent hypotheses using the selection rule based on estimated eﬀect diﬀerences; ∆+ =
0.5; total sample size determined to assure a power of 80% at t = 0.5.
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Table 4.1: Minimal, maximal and range of power (probability to reject H
(0)
0 or H
(+)
0 )
for t ∈ [0.3, 0.7] applying selection rule based on estimated eﬀect diﬀerences; ∆+ = 0.5;
total sample size (n) determined to assure a power of 80% at t = 0.5.
minimal power maximal power
c p ∆− ∆0 n t power t power power range
0 0.2 0.1 0.18 157 0.7 0.72 0.35 0.815 0.095
0.3 0.34 120 0.7 0.742 0.3 0.833 0.091
0.5 0.50 81 0.7 0.766 0.3 0.834 0.068
0.4 0.1 0.26 115 0.7 0.753 0.3 0.816 0.063
0.3 0.38 98 0.7 0.771 0.3 0.822 0.052
0.5 0.50 74 0.7 0.785 0.3 0.817 0.031
0.7 0.1 0.38 86 0.7 0.788 0.3 0.813 0.025
0.3 0.44 79 0.7 0.793 0.3 0.813 0.02
0.5 0.50 70 0.7 0.799 0.3 0.812 0.013
0.2 0.2 0.1 0.18 232 0.3 0.788 0.575 0.8 0.012
0.3 0.34 129 0.7 0.772 0.3 0.824 0.052
0.5 0.50 77 0.7 0.79 0.3 0.823 0.033
0.4 0.1 0.26 153 0.7 0.794 0.35 0.802 0.008
0.3 0.38 106 0.7 0.789 0.3 0.815 0.026
0.5 0.50 72 0.7 0.8 0.3 0.814 0.014
0.7 0.1 0.38 101 0.7 0.795 0.3 0.808 0.012
0.3 0.44 84 0.7 0.797 0.3 0.81 0.013
0.5 0.50 69 0.675 0.796 0.3 0.809 0.013
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Type I Error Rate
The type I error rate depending on diﬀerent interim analysis timings is investigated for
three diﬀerent types of null distributions:
 ∆0 = 0, ∆+ = 0.3 (only H
(0)
0 is true)
 ∆0 = 0.3, ∆+ = 0 (only H
(+)
0 is true)
 ∆0 = 0, ∆+ = 0 (H
(0)
0 and H
(+)
0 are true).
The size of ∆− depends on the prevalence of the subgroup in the speciﬁc scenario. For
the ﬁrst case with ∆0 = 0 and ∆+ = 0.3, ∆− is equal to −0.075 for p = 0.2, ∆− = −0.2
for p = 0.4 and ∆− = −0.7 for p = 0.7. For the second null scenario with ∆0 = 0.3 and
∆+ = 0, ∆− = 0.375 for p = 0.2, ∆− = 0.5 for p = 0.4 and ∆− = 1 for p = 0.7. If both
null hypotheses are true, ∆− = 0 for each prevalence. A sample size of n = 200 is used
in each scenario. The global one-sided signiﬁcance level was set to 0.025. To control the
familywise error rate in the strong sense, the closure principle including Simes' correction
to test the intersection hypothesis is applied. Figure 4.3 shows the type I error rate for
the diﬀerent null scenarios. In agreement with theory, the probability to reject one null
hypothesis is smaller than the chosen α-level of 0.025. Obviously, the probability to
reject the null hypothesis which is not true is larger than 0.025 and is not shown in the
diagrams.
If only H
(0)
0 is true and ∆+ = 0.3, the probability to reject H
(0)
0 is smaller than 0.01
in every considered scenario and decreases with increasing interim analysis timing. Fur-
thermore, the type I error rate is slightly higher for higher c since in this case the total
population is selected with a higher probability. In case H
(+)
0 is true and ∆0 = 0.3, the
type I error rate decreases with increasing t for most of the scenarios. However, for c = 0
and p = 0.2 the probability to reject H
(+)
0 increases for late interim analysis timings. In
case both null hypotheses are true, the probability to reject either H
(+)
0 or H
(0)
0 has kind
of a slightly u-shaped form for most scenarios. Since only one hypothesis is tested at
the end of the trial when using the selection rule based on estimated eﬀect diﬀerences,
this probability is the sum of the probability to reject H
(+)
0 and the probability to reject
H
(0)
0 . While the familywise error rate lies slightly below 0.025 for very early and very late
timings, an interim analysis in between leads to rather conservative decisions. Only for
the scenario with c = 0.2 and p = 0.7, the familywise error rate decreases with increasing
t.
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(a) c = 0
(b) c = 0.2
Figure 4.3: Type I error rate for diﬀerent interim analysis timings in caseH
(0)
0 , H
(+)
0 and
both hypotheses are true using the selection rule based on estimated eﬀect diﬀerences;
n = 200.
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4.2.3 Selection Rule Based on Absolute Eﬀect Estimates
In this section, results are presented using the selection rule based on absolute treatment
eﬀect estimates. Threshold values are set to c0 = 0.1 and c+ = 0.1, 0.3.
Power
Using the selection rule based on absolute eﬀect estimates, selection of a co-primary
analysis where H
(+)
0 and H
(0)
0 is tested in the ﬁnal analysis is also possible. Thus, the
power deﬁned as the probability to reject either H
(+)
0 , H
(0)
0 or both is considered. Again,
the sample size in each scenario is calculated to assure a power of 80% for an interim
analysis timing of 0.5. Power characteristics are presented in Table 4.2 and Figure 4.4 for
diﬀerent scenarios. In addition, probabilities for the diﬀerent interim decisions and the
respective rejection probabilities are displayed in Figure 4.5 for c+ = 0.1 and in Figure
4.6 for c+ = 0.3.
In contrast to the selection rule based on estimated eﬀect diﬀerences, the power is small
for early interim analysis timings. Considering the power only for timings in the interval
of t ∈ [0.3, 0.7], the power is smallest for t = 0.3 (see Table 4.2) in every scenario. The
small power for early timings using the selection rule based on absolute eﬀect estimates
results from the additional possibility to stop for futility. This is more likely at the
beginning of the trial due to the lower precision of the eﬀect estimates for small sample
sizes, which is depicted by the orange dotted line in Figure 4.5 and Figure 4.6.
In Figure 4.4a, showing results for p = 0.2 and c+ = 0.1, the power is more or less con-
stant for t > 0.4 and ∆− > 0.25. Furthermore, the power ranges for t ∈ [0.3, 0.7] amount
to about 1% only, implying that the timing of the interim analysis in the considered
interval has no substantial eﬀect on the power of the study. However, the timing of the
interim analysis has an impact on the selection probabilities (see Figure 4.5, p = 0.2,
∆− = 0.5): While the probability to select both populations increases with increasing
t, the probability to select only a single population decreases with increasing interim
analysis timing. In contrast, for ∆− = 0.1 (and p = 0.2), the overall power decreases for
later timings. In this case, the probability to select only the subgroup is higher compared
to scenarios with higher ∆−. If only G+ is selected, the power decreases with increasing
interim analysis timings. While for early interim analysis timings, H
(+)
0 is rejected with
a high probability if G+ is selected, the probability to reject H
(+)
0 in case the subgroup
is selected declines for timings after around t = 0.5. This results from a rather small
sample size of G+ if the subgroup is selected as target population towards the end of the
study. This small conditional probability of rejecting H
(+)
0 given that the subgroup is
selected for late timings is especially striking for small prevalence.
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In case of a higher prevalence (see Figure 4.4 c and e), the decline of the power for small
∆− is less pronounced or not present since the probability to select only the subgroup
is smaller for scenarios with a higher prevalence due to the higher eﬀect in the overall
population.
In case the threshold for selecting the subgroup is higher, the probability to select the
subgroup is obviously smaller. Figure 4.4 b, d and f as well as Figure 4.6 show the power
characteristics for c+ = 0.3. In comparison to the scenarios with c+ = 0.1, the power
increases also for later timings in many scenarios. For example, the maximal power
diﬀerence is 10.0% for ∆− = 0 and p = 0.2.
This can be explained by the fact that the power loss for later timings in case only the
subgroup is selected is not present in this case. Firstly, the probability to select G+ only
is much smaller, and secondly, if G+ is selected, the estimated eﬀect size from the ﬁrst
stage must be larger than 0.3 and thus, a rejection of H
(+)
0 is more likely as compared
to the selection rule using c+ = 0.1. Moreover, the overall sample size needed to achieve
a power of 80% at t = 0.5 is higher using the stricter selection rule especially for the
scenario p = 0.2 and ∆− = 0.1 where sample size is around 25% higher (see Table 4.2).
Overall, the power is smallest for t = 0.3 in each considered scenario and maximal for
timings between 0.5 and 0.7. However, the power range within the interval [0.3, 0.7] is
not very high in most situations, and the power of 80% at a timing of t = 0.5 is not much
improved for later timings. The highest power gain is achieved for c+ = 0.3, p = 0.2 and
a small ∆−. For example, for ∆− = 0.1 the overall power of 82.7% is reached for t = 0.7,
which cannot be regarded as a considerably high gain though.
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Table 4.2: Minimal, maximal and range of power (probability to reject H
(0)
0 , H
(+)
0
or both) for t ∈ [0.3, 0.7] applying selection rule based on absolute eﬀect estimates;
∆+ = 0.5; c0 = 0.1; total sample size (n) determined to assure a power of 80% at
t = 0.5.
minimal power maximal power
c+ p ∆− ∆0 n t power t power power range
0.1 0.2 0.1 0.18 262 0.3 0.772 0.575 0.804 0.032
0.3 0.34 149 0.3 0.795 0.5 0.803 0.008
0.5 0.50 78 0.3 0.793 0.7 0.803 0.010
0.4 0.1 0.26 157 0.3 0.784 0.525 0.801 0.017
0.3 0.38 116 0.3 0.791 0.525 0.803 0.012
0.5 0.50 77 0.3 0.79 0.7 0.804 0.014
0.7 0.1 0.38 100 0.3 0.783 0.7 0.804 0.02
0.3 0.44 88 0.3 0.783 0.675 0.806 0.023
0.5 0.50 75 0.3 0.783 0.675 0.806 0.022
0.3 0.2 0.1 0.18 329 0.3 0.76 0.7 0.827 0.067
0.3 0.34 151 0.3 0.783 0.675 0.804 0.021
0.5 0.50 77 0.3 0.787 0.7 0.803 0.016
0.4 0.1 0.26 182 0.3 0.763 0.7 0.823 0.06
0.3 0.38 118 0.3 0.776 0.675 0.809 0.033
0.5 0.50 76 0.3 0.783 0.675 0.806 0.023
0.7 0.1 0.38 106 0.3 0.762 0.7 0.818 0.056
0.3 0.44 89 0.3 0.768 0.7 0.812 0.044
0.5 0.50 75 0.3 0.778 0.7 0.812 0.033
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(a) p = 0.2, c+ = 0.1 (b) p = 0.2, c+ = 0.3
(c) p = 0.4, c+ = 0.1 (d) p = 0.4, c+ = 0.3
(e) p = 0.7, c+ = 0.1 (f) p = 0.7, c+ = 0.3
Figure 4.4: Probability to reject H
(0)
0 , H
(+)
0 or both using the selection rules based on
absolute eﬀect estimates; ∆+ = 0.5; c0 = 0.1; total sample size determined to assure a
power of 80% at t = 0.5.
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Figure 4.5: Probability for diﬀerent interim decisions, and probability to reject diﬀerent
hypotheses using the selection rule based on absolute eﬀect estimates; ∆+ = 0.5; c0 = 0.1;
c+ = 0.1; total sample size determined to assure a power of 80% at t = 0.5.
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Figure 4.6: Probability for diﬀerent interim decisions, and probability to reject diﬀerent
hypotheses using the selection rule based on absolute eﬀect estimates; ∆+ = 0.5; c0 = 0.1;
c+ = 0.3; total sample size determined to assure a power of 80% at t = 0.5.
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Type I Error Rate
Figure 4.7 depicts the type I error rate for the three null scenarios considered previously:
only H
(0)
0 is true (∆0 = 0,∆+ = 0.3), only H
(+)
0 is true (∆0 = 0.3,∆+ = 0) and both null
hypotheses are true (∆0 = 0,∆+ = 0). In contrast to the type I error rate investigations
for the selection rule based on estimated eﬀect diﬀerences, where the rejection probabil-
ities are presented separately for each interim decision, in this section the probabilities
to reject H
(+)
0 (in case ∆0 = 0,∆+ = 0.3), H
(0)
0 (in case ∆0 = 0.3,∆+ = 0) and at least
one of the hypotheses (in case ∆0 = 0,∆+ = 0) are considered irrespective of the interim
decision.
In the considered scenarios, the type I error rate never exceeds the alpha level of 0.025.
In most cases, early interim timings are rather conservative, and the probability to reject
a true null hypothesis increases with increasing t. For late interim analysis timings, the
type I error reaches almost 0.025 for most of the scenarios. One exception is the scenario
∆0 = 0.3,∆+ = 0, p = 0.7 and c+ = 0.3 shown in 4.7b, where the type I error rate
decreases with increasing t.
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(a) c+ = 0.1
(b) c+ = 0.3
Figure 4.7: Type I error rate for diﬀerent interim analysis timings in case H
(0)
0 , H
(+)
0
and both hypotheses are true using the selection rule based on absolute eﬀect estimates;
n = 200.
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4.3 Clinical Trial Example
In this section, the impact of the interim analysis timing on the power of the study is
investigated for a clinical trial example from the ﬁeld of pneumonology. The MILLY
trial is a randomized, double-blind, placebo-controlled clinical trial investigating the
eﬃcacy of lebrikizumab for patients with uncontrolled asthma (Corren et al., 2011). The
primary endpoint was the relative change in prebronchodilator forced expiratory volume
in 1 second from baseline to week 12. It was supposed that the treatment eﬀect was
higher for patients with a high serum periostin level as well as for patients with high
type 2 helper T-cell (Th2) status. The MILLY trial was conducted as a single-stage
study. Subgroup analyses were performed for prespeciﬁed subgroups deﬁned by high
and low periostin levels as well as high and low Th2 levels. For illustrative purposes,
it is assumed that the trial was planned as a two-stage adaptive enrichment design. It
is assumed that the observed treatment eﬀects in the MILLY trial are the true eﬀects
and the standard deviation equals 19%, which was used for sample size calculation. This
leads to the eﬀect sizes ∆per+ = 0.43 and ∆per− = 0.08 for subgroups deﬁned by high and
low periostin levels, and ∆Th2+ = 0.34 and ∆Th2− = 0.25 for subgroups deﬁned by high
and low Th2 levels. A prevalence of 0.5 is assumed for each biomarker, respectively. As
for the selection rules described in the previous sections, thresholds of c = 0 and c = 0.2
are considered when using the selection rule based on estimated eﬀect diﬀerences, and
c0 = 0.1 together with c+ = 0.1 and c+ = 0.3 when using the selection rule based on
absolute eﬀect estimates. The sample size is calculated for each biomarker and the used
threshold values to assure a power of 80% for an interim analysis timing at t = 0.5 in
the speciﬁc scenario.
Figure 4.8 shows the power and selection probabilities for the selection rule based on
estimated eﬀect diﬀerences. When considering periostin level to deﬁne the subgroup
(see Figure 4.8a), eﬀect sizes diﬀer considerably between both populations. For c = 0,
this leads to a power maximum at around t = 0.3. With an overall sample size of 140,
the timing of 0.3 corresponds to a sample size of 42 in the ﬁrst stage and 98 in the second
stage. If the subgroup with high periostin levels is selected, the number of patients to
test the eﬀect in the subgroup is 119. In case the total population is selected, all enrolled
patients are included in the ﬁnal analysis testing the eﬀect in the total population. For
late interim analyses, the probability is high to select the population with high periostin
values but the probability to reject the null hypothesis related to this subgroup decreases
as the sample size in this subgroup decreases with increasing interim analysis timing.
For example, an interim analysis performed at t = 0.7 leads to a sample size of only 91
in case the subgroup is selected.
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For c = 0.2, the power decreases very slightly with increasing t. In this case, the
probability is higher to select the total population. The eﬀect size of the total population
is 0.255 and hence, the diﬀerence to ∆per+ is with 0.175 slightly smaller than c = 0.2.
Furthermore, the conditional rejection probabilities for both interim decisions seems to
be relatively constant. The higher sample size for c = 0.2 and the higher eﬀect estimate
from the ﬁrst stage in G+ are probably the main reasons that power does not decline
considerably if the subgroup is selected. Thus, the impact of the choice of the interim
analysis timing on the overall power of the study is negligible in this scenario.
In the setting using Th2 level as biomarker, the eﬀect sizes are similar between both
populations, and therefore, it is advantageous in terms of power to conduct an early
interim analysis.
Figure 4.9 shows the selection and rejection probabilities for the diﬀerent populations
and hypotheses when using the selection rule based on absolute eﬀect estimates. In each
scenario, both populations are selected in the with a relatively high probability, which is
the correct decision in every considered setting. Due to the option to stop for futility, the
overall probability to reject at least one hypothesis is smaller for early interim analysis
timings as already described in Subsection 4.2.3. For c+ = 0.1, the power is more or
less constant after around t = 0.4 for both considered biomarker settings. For c+ = 0.3,
the power also slightly increases for later timings, which suggests that later timings are
more favourable when using the stricter c+. However, the power gain is not substantial.
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(a) Subgroups deﬁned by periostin level, ∆per+ = 0.43 and ∆per− = 0.08,
n = 140 for c = 0, n = 190 for c = 0.2
(b) Subgroups deﬁned by Th2 level, ∆Th2+ = 0.34 and ∆Th2− = 0.25,
n = 182 for c = 0, n = 192 for c = 0.2
Figure 4.8: Probability to select G+ and G0, and probability to reject diﬀerent hypothe-
ses using the selection rule based on estimated eﬀect diﬀerences for eﬀects observed in
the MILLY trial.
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(a) Subgroups deﬁned by periostin level, ∆per+ = 0.43 and ∆per− = 0.08, n = 179
for c+ = 0.1, n = 214 for c+ = 0.3
(b) Subgroups deﬁned by Th2 level, ∆Th2+ = 0.34 and ∆Th2− = 0.25, n = 205 for
c+ = 0.1, n = 209 for c+ = 0.3
Figure 4.9: Probability for diﬀerent interim decisions, and probability to reject diﬀerent
hypotheses using the selection rule based on absolute eﬀect estimates for eﬀects observed
in the MILLY trial; c0 = 0.1.
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4.4 Chapter Summary
In this chapter, the impact of diﬀerent interim analysis timings was investigated using
an adaptive enrichment design with a prespeciﬁed ﬁxed overall sample size. Results were
obtained using simulation studies since an analytical derivation of the power function was
not possible. In addition to the investigation of simulation studies for various scenarios,
ﬁndings were demonstrated by a clinical trial example.
Results of simulation studies show that there are indeed situations in which the timing
of the interim analysis has an impact on power. In particular, diﬀerent selection rules
lead to diﬀerent power characteristics for varying interim analysis timings.
Using the selection rule based on diﬀerences of eﬀect estimates, where a test for eﬃcacy
is conducted either in the subgroup or the total population at the end of the trial, early
timings are in general more favorable in terms of power. Power ranges are especially
high and thus, the timing should be selected with special care if the prevalence and the
threshold value c is small. In this case, the power is small for late timings since if the
subgroup is selected, only a small fraction of the ﬁrst-stage data can be used, which leads
to a small overall sample size of the subgroup. Therefore, late interim analyses should
be avoided in case the prevalence is small and c is not too strict. Furthermore, power is
maximal at extremely early timings and decreases for increasing interim analysis time
if both the eﬀect in the subgroup and the total population are high. In this case, it is
irrelevant in terms of power which population is selected in an early interim analysis,
but the sample size in the subgroup is smaller for later interim analysis timings. On
the contrary, the probability to select the correct population is not very high for early
interim analyses. When using a higher threshold value c it is less likely to select only
the subgroup, which is more useful in practice to prevent such a restrictive selection.
Furthermore, the power is more stable over diﬀerent interim analysis timings for a higher
c. Moreover, power is relatively constant for diﬀerent interim analysis timings if the
prevalence is high irrespective of the choice of c.
Using the selection rule based on absolute eﬀect estimates that additionally includes
the option to stop the trial for futility as well as selection of both populations, the
power is small for early interim analysis timings. Whether power decreases, increases,
or stays relatively constant after t = 0.5 depends on the chosen threshold values, the
prevalence, and the treatment eﬀects. A reason for the small power when conducting
early interim analyses is the probability to stop for futility that decreases with increasing
interim timing. Therefore, applying this selection rule at the end of the trial is pointless.
However, simulation results illustrate that in many scenarios, power is approximately
constant or increases only slightly after t ≈ 0.5 which makes an interim analysis around
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t = 0.5 meaningful in these cases.
Besides, the type I error rate was investigated for three diﬀerent null scenarios. In each
considered scenario, type I error rate or rather familywise error rate was controlled. The
size of the actual type I error rate depends on the considered parameters.
In summary, using the selection rule based on estimated eﬀect diﬀerences, in general,
early interim analysis timings lead to a power advantage. In particular, scenarios with
small prevalence and small c showed a considerable small power for later interim analysis
timings. In these settings, late interim analysis timings should be avoided. In contrast,
for large prevalence and large c, the timing of the interim analysis does not have a major
impact on the power of the study. On the contrary, using the selection rule based on
absolute eﬀect estimates, early timings should be avoided since the option to stop for
futility leads to a small power for interim analyses conducted at the beginning of the
study.
To conclude, the power of a study can diﬀer considerably for diﬀerent interim analy-
sis timings in many scenarios. Power characteristics depend on the selection rule, the
prevalence, and eﬀect sizes. However, in many situations, there were no large power
gains for timings before or after a timing of 0.5. Nevertheless, no general rules could
be established and no speciﬁc timing of the interim analysis can be recommended that
uniformly ﬁts to all scenarios.
Eventually, when choosing the interim analysis timing in the planning phase of a study,
not only the power should be taken into account but also the probability to stop for
futility and other selection probabilities. This is especially true if the highest power
occurs for an interim analysis at the beginning or at the end of a study.
Chapter 5
Design with Sample Size Reassessment
In this chapter, an adaptive enrichment design with sample size reassessment is consid-
ered where not only the population is selected in the interim analysis but also the sample
size of the second stage is recalculated. For this design, diﬀerent interim analysis timings
are compared regarding the distribution of the recalculated sample size. For this issue,
the deﬁnition of the timing of the interim analysis has to be modiﬁed. If the overall
sample size is not ﬁxed, the deﬁnition of the interim analysis timing as a ratio of the
number of patients in the ﬁrst stage (nI) and the total sample size (n) as used in the
previous chapter is not appropriate. Instead, the ratio of nI and the sample size required
in a ﬁxed design without interim analysis (nfix) is considered, that is t = n
I/nfix, where
the sample size for the ﬁxed design is given by
nfix =
2(z1−α/4 + z1−β)2
∆20,A
, (5.0.1)
and ∆0,A is the assumed eﬀect in G0 under the alternative hypothesis. Since the pop-
ulation to be tested is not speciﬁed in the planning phase, the sample size formula
incorporates the Bonferroni adjustment using z1−α/4.
This chapter has the following structure. In Section 5.1, the general methodology of
sample size reassessment is described. Simulation studies were conducted to investigate
characteristics of diﬀerent interim analysis timings. Results are presented in Section 5.2
for the two selection rules: based on estimated eﬀect diﬀerences and based on absolute
eﬀect estimates. Thereafter, in Section 5.3, the sample size distribution for diﬀerent
interim analysis timings is investigated for the clinical trial example that was already
described in the previous chapter. At the end of the chapter, results are summarized in
Section 5.4.
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5.1 Methods for Sample Size Reassessment
In the previous chapter, the overall sample size was ﬁxed in advance, and only the
composition of the population in the second stage (G0 or G+) was adapted. However,
an adaptive design oﬀers also the possibility to recalculate the sample size based on the
eﬀects observed in the interim analysis. This option is especially useful if there is a
considerable uncertainty with regard to the treatment eﬀects assumed in the planning
stage. The basic idea is to adjust the sample size upwards if the observed eﬀect in the
interim analysis is smaller than expected, and downwards if the observed eﬀect is higher
than expected. In the setting of adaptive enrichment designs, the sample size for the
selected population is reassessed to assure the sample size is suﬃcient to reject H
(+)
0 or
H
(0)
0 , depending on which of these two hypotheses is selected, with a certain probability.
For the design incorporating sample size reassessment, test statistics for the single stages
(ZI0 , Z
I
+, Z
II
0 , Z
II
+ ) given in formulas (3.3.1), (3.3.2), (3.3.3), (3.3.4) remain valid. How-
ever, the weights to combine the single test statistics from the ﬁrst and the second stage
using the inverse normal combination method have to be modiﬁed. In the ﬁxed sample
size setting, the weights were chosen so that they reﬂect the sample sizes in both stages.
However, if sample size recalculation is applied, the ratio of the ﬁrst and second-stage
sample size is not known in the planning phase where weights have to be speciﬁed. There-
fore, weights are chosen as
√
t and
√
1− t for the ﬁrst- and second-stage test statistics,
respectively, with t = nI/nfix irrespective of whether G0 or G+ is selected. Thus, in each
formula addressing the combination using the inverse normal method, the redeﬁned t is
used, and formula (3.3.6) changes to
Z+ =
√
tZI+ +
√
1− tZII+ . (5.1.1)
Even if these weights do not correspond to the actual sample size allocation in both
stages, the loss in power is relatively small (Lehmacher and Wassmer, 1999).
The most commonly used method to recalculate the sample size in the interim analysis is
based on conditional power arguments (Proschan and Hunsberger, 1995). The idea of this
approach is to calculate the sample size in the second stage so that a speciﬁc probability
to reject a given null hypothesis conditional on the observed test statistic in the ﬁrst
stage is assured for a certain assumed eﬀect size. When using the described adaptive
enrichment design, the second-stage sample size nII+ or n
II
0 is recalculated depending on
the interim decision. The assumed eﬀects under the alternative hypotheses used in the
interim analysis for sample size recalculation are denoted by ∆0,A˜ for G0 and ∆+,A˜ for
the eﬀect in G+. There are diﬀerent approaches for specifying the assumed eﬀects. One
possible method is to adhere to the assumed eﬀect from the planning phase (∆0,A for
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the eﬀect in G0 and ∆+,A for the eﬀect in G+). Another approach is to use the eﬀect
estimate observed in the interim analysis for sample size recalculation, i.e. ∆0,A˜ = ∆ˆ0
and ∆+,A˜ = ∆ˆ+. A combination of both approaches can be achieved using the Bayesian
posterior mean, that is a weighted sum of the prior density mean and the observed eﬀect
size in the interim analysis (Wassmer and Brannath, 2016, page 180). As a special case,
for example, the mean value ∆+,A˜ = (∆+,A + ∆ˆ+)/2 or ∆0,A˜ = (∆0,A + ∆ˆ0)/2 for the
eﬀect in G+ and G0, respectively, can be used.
In the situation that G+ is selected at interim, the conditional power for the rejection of
H
(+)
0 is given by
CP = Pr∆+,A˜
(
Z+ ≥ z1−α/4
∣∣ ZI+ )
= Pr∆+,A˜
(√
tZI+ +
√
1− tZII+ ≥ z1−α/4
∣∣ ZI+)
= Pr∆+,A˜
(
ZII+ ≥
z1−α/4√
1− t −
√
t
1− tZ
I
+
∣∣∣∣ ZI+
)
= Pr∆+,A˜
((
∆ˆII+ −∆+,A˜
)√nII+
2
≥ z1−α/4√
1− t −
√
t
1− tZ
I
+ −∆+,A˜
√
nII+
2
∣∣∣∣ ZI+
)
= 1− Φ
(
z1−α/4√
1− t −
√
t
1− tZ
I
+ −∆+,A˜
√
nII+
2
)
,
where the Bonferroni correction was incorporated to adjust for multiple testing. From
this equation it follows the required sample size nII+ for the conditional power CP and
the assumed eﬀect size ∆+,A˜:
z1−CP =
z1−α/4√
1− t −
√
t
1− tZ
I
+ −∆+,A˜
√
nII+
2
⇒ nII+ =
2
∆2
+,A˜
(
z1−α/4√
1− t −
√
t
1− tZ
I
+ − z1−CP
)2
.
The term in brackets can become negative if ZI+ > z1−α/4/
√
t− z1−CP
√
(1− t)/t. Since
this corresponds to extremely large test statistics, negative values are set to zero. Fur-
thermore, ∆+,A˜ can become negative if the observed interim eﬀect is included in ∆+,A˜. In
this case, ∆+,A˜ is set to 0. Moreover, the recalculated sample size can get impracticably
high if small eﬀects are observed in the interim analysis. Therefore, it may be advisable
to restrict the sample size in the second stage to nIImax. In particular, the sample size is
nIImax if the assumed eﬀect in the interim analysis is negative. However, this situation
does not occur when using the selection rule based on absolute eﬀect estimates. Here,
the study is stopped for futility if negative eﬀects are observed, and sample size recalcu-
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lation is not conducted at all. In order to apply the inverse normal combination method,
where data in stage II is necessary, also a minimal second-stage sample size nIImin should
be chosen. With the restrictions described above, the sample size formula is modiﬁed to
nII+ = max
nIImin,min
nIImax, 2(∆+,A˜)2+
(
z1−α/4√
1− t −
√
t
1− tZ
I
+ − z1−CP
)2
+

 (5.1.2)
where (x)+ := max(x, 0).
The conditional power in case the total population is selected, can be derived in the
same way, and is given by
CP = 1− Φ
(
z1−α/4√
1− t −
√
t
1− tZ
I
0 −∆0,A˜
√
nII0
2
)
.
With the same restrictions as described for recalculating the sample size of the subgroup,
this leads to the sample size formula for the second stage in case G0 is selected:
nII0 = max
nIImin,min
nIImax, 2(∆0,A˜)2+
(
z1−α/4√
1− t −
√
t
1− tZ
I
0 − z1−CP
)2
+

 . (5.1.3)
It should be noted that the limits of sample size nIImin and n
II
max do not necessarily have
to agree in the calculation of nII+ and n
II
0 . However, for practical reasons, limits are
assumed to be equal for each interim decision.
In summary, the following approach is considered in this thesis. When using the selec-
tion rule based on estimated eﬀect diﬀerences, the sample size for the second stage is
calculated using formula (5.1.2) if G+ is selected as target population and formula (5.1.3)
if G0 is selected. When using the selection rule based on absolute eﬀect estimates, the
same procedure is applied if only one population is selected. If the co-primary analy-
sis is chosen, which means patients from G0 are enrolled in the second stage and both
hypotheses are tested in the ﬁnal analysis, nII0 and n
II
+ is calculated with the described
formulas and ﬁnally, the maximum sample size of nII0 and n
II
+ /p is used overall in the
second stage to assure the conditional power for both hypotheses. If the observed eﬀects
suggest a futility stop, nII = 0.
Moreover, it should be noted that Bonferroni adjustment is applied when using the design
including sample size recalculation for the sake of simplicity. Sample size calculation
when applying Simes' method for testing the intersection hypothesis within the closed
testing procedure is more challenging since it is not clear in the interim analysis which
hypothesis is tested at which local signiﬁcance level.
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5.2 Simulation Study
In this section, results of simulation studies are presented for an adaptive enrichment
design with sample size reassessment in the interim analysis using conditional power
arguments as described in the previous section. Here, the impact of the interim analysis
timing on overall sample size distribution is investigated.
5.2.1 Simulation Setup
In the conducted simulation studies, sample sizes are calculated using formulas (5.1.2)
and (5.1.3) with a minimum second-stage sample size of nIImin = 10 (if the trial is not
stopped for futility) and a maximum sample size in the second stage of nIImax = 2nfix−nI .
Hence, the total sample size is never higher than twice the sample size calculated in a
ﬁxed design without interim analysis. Moreover, two diﬀerent methods are considered
for choosing the assumed eﬀect size in the interim analysis that is used for sample size
recalculation. The ﬁrst one is to adhere to the assumed eﬀect size from the planning
phase, i.e. ∆+,A˜ = ∆+,A and ∆0,A˜ = ∆0,A, while the second considered approach is to
use the mean of the eﬀect size from the planning phase and the observed eﬀect in the
interim analysis, that is ∆+,A˜ = (∆+,A+∆ˆ+)/2 and ∆0,A˜ = (∆0,A+∆ˆ0)/2. Furthermore,
in the simulations, the assumed eﬀect size used in the planning phase is equal to the true
eﬀect size, i.e. ∆+,A = ∆+ and ∆0,A = ∆0. The Bonferroni method is used to handle
the underlying multiple testing problem.
Characteristics of the sample size distribution are investigated for interim analysis tim-
ings of t = 0.2, 0.35, 0.5, 0.65, 0.8. In order to make the distributions comparable for
diﬀerent interim analysis timings, the conditional power is adapted in each scenario to
reach an overall power of 80%. The corresponding conditional power is determined using
simulations.
Furthermore, results for diﬀerent eﬀect sizes, prevalences and selection rules are pre-
sented. The eﬀect in G+ is equal to ∆+ = 0.5 in each scenario, the eﬀect in G− varies
with ∆− = 0, 0.25, 0.5, and diﬀerent prevalences are investigated using p = 0.2, 0.7. As in
the previous chapter, diﬀerent parameters for the selection rules are considered. For the
selection rule based on estimated eﬀect diﬀerences, results for c = 0 and c = 0.2 are pre-
sented. When using the selection rule based on absolute eﬀect estimates, c0 = 0 in every
scenario and c+ = 0.1, 0.3. For each scenario, 1, 000, 000 study results are simulated.
In the following, results are presented for the selection rule based on estimated eﬀect
diﬀerences and the selection rule based on absolute eﬀect estimates. For both selection
rules, ﬁrstly, results using the eﬀect size from the planning phase for sample size reassess-
ment and secondly, using the mean of the assumed eﬀect from the planning phase and
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the observed eﬀect in the interim analysis are shown.
5.2.2 Selection Rule Based on Estimated Eﬀect Diﬀerences
In this section, characteristics of the sample size distribution are investigated for the
selection rule based on estimated eﬀect diﬀerences. Distribution of sample size is depicted
by stacked histograms for both interim decisions, where the total sample size is shown
in red color if G+ is selected, and in blue color if G0 is selected. It should be noted that
histograms are used to demonstrate the distribution of the sample size and frequencies
cannot be compared directly for diﬀerent interim analysis timings since the y-axis scaling
is not consistent for diﬀerent timings. Additionally, the distribution of the sample size
irrespective of the interim decision is summarized by boxplots showing median, ﬁrst and
third quartile and mean (marked by a dot). Further characteristics are given in the
tables to the right of the ﬁgures. Here, the average sample size ± standard deviation
(ASS ± SD), the probability for selection of G+, the adjusted conditional power to reach
an overall power of 80%, and the probability for n > nfix is given.
5.2.2.1 Using the Eﬀect Size from the Planning Phase for Sample Size Re-
assessment
In the ﬁrst part of this subsection, characteristics of the sample size distribution are
investigated using the assumed eﬀect size from the planning phase to recalculate the
sample size in the interim analysis. Results for c = 0 are presented in Figure 5.1 and
Figure 5.2 for p = 0.2 and p = 0.7, respectively.
If the overall treatment eﬀect ∆0 is small, which is the case in the considered settings if
p and ∆− are small, the originally planned sample size nfix is high (see Figure 5.1a with
p = 0.2, ∆− = 0, ∆0 = 0.1, nfix = 1902). In this case, an early interim analysis clearly
leads to the smallest average sample size. The reason is that an early interim analysis
of t = 0.2 results in a relatively high sample size in the ﬁrst stage (nI = 380) due to the
large nfix. The high sample size and the large diﬀerence between ∆0 and ∆+ lead to a
high probability (99.7%) to select G+. Due to the high eﬀect in the subgroup, only a
small sample size is required for the second stage. This is also reﬂected by the conditional
power of 0 for t ≥ 0.35 in the described scenario. In this case, the sample size in the
ﬁrst stage is suﬃcient to detect an eﬀect with a probability of at least 80%. Therefore,
only 10 patients per group are included in the second stage, and the power can be higher
than 80%. In this scenario, the power is 85.8% for t = 0.35, 97.7% for t = 0.5, 99.8%
for t = 0.65, and > 99.9% for t = 0.8. It should be noted that a conditional power of
0 for sample size recalculation means that the minimal sample size of nIImin is used and
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that this sample size is suﬃcient to reach an overall power of at least 80%. However, the
actual conditional power might be larger.
For scenarios with higher ∆−, median and mean values of the sample size are more
similar when comparing diﬀerent interim analysis timings. For ∆− = 0.25 (Figure 5.1b),
the average sample size is still increasing for increasing t and the standard deviation
decreases. However, the probability for n > nfix is smallest for t = 0.5. A further
advantage of using t ≈ 0.5 as compared to earlier interim analysis timings is the higher
probability to select G+, which is the correct decision in this scenario. For later interim
analysis timings, the sample size in the second stage is the minimum sample size with a
probability near 1, which shows that late interim analyses are meaningless.
If the eﬀects in G− and G+ are equal (Figure 5.1c), the average sample size is still slightly
increasing for increasing t but median sample sizes as well as the probability for n > nfix
are very similar for diﬀerent timings of the interim analysis. In this case, the main
diﬀerence lies in the distribution of the sample size. While the distribution of the sample
size for early interim analysis timings is rather symmetric around the mean, for later
interim analysis timings, it becomes more likely that the second stage is conducted with
the minimal sample size. This means that if the interim analysis is performed relatively
late, it is not possible to get a small overall sample size due to the large ﬁrst-stage sample
size. Furthermore, in this scenario, it is unlikely that a very large sample size is required
for the second stage of the trial. When doing the interim analysis early, both options
(small and large overall sample size) are possible.
If the prevalence of the subgroup is higher (Figure 5.2), ∆0 is higher (except for ∆− = 0.5)
and thereby, nfix is smaller. For ∆− = 0, p = 0.7 (Figure 5.2a), the average sample size
is more similar across diﬀerent timings than in the scenario with p = 0.2. Although
the smallest average sample size occurs for t = 0.2, an early interim analysis has some
disadvantages: the probability to select G0, is rather high with 18%, and if G0 is selected
the recalculated sample size is also rather high due to the smaller eﬀect size.
For higher eﬀects, the smallest average sample size occurs for later interim analysis
timings compared to the respective scenarios with p = 0.2. While for p = 0.2, the smallest
average sample size is observed for a timing of t = 0.2 irrespective of ∆−, the timing
with the smallest average sample size is present for t = 0.2, 0.35, 0.5 for ∆− = 0, 0.25, 0.5
in case p = 0.7. This means, if the prevalence is higher, the smallest average sample size
is reached for later interim analysis timings. This is reasonable since more data from
the ﬁrst stage can be used if the subgroup is selected in case the prevalence is higher.
Thus, a late interim analysis does not lead to a large loss of information as compared to
scenarios with a smaller prevalence.
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t ASS± SD G+ sel. CP n > nfix
0.2 412± 84 0.997 0.8 0.001
0.35 676± 0 > 0.999 0 0
0.5 961± 0 > 0.999 0 0
0.65 1246± 0 > 0.999 0 0
0.8 1532± 0 > 0.999 0 0
(a) p = 0.2,∆− = 0,∆0 = 0.1, c = 0, nfix = 1902
t ASS± SD G+ sel. CP n > nfix
0.2 134± 63 0.678 0.81 0.142
0.35 142± 56 0.728 0.8 0.104
0.5 157± 49 0.767 0.79 0.087
0.65 174± 42 0.797 0.75 0.112
0.8 197± 37 0.822 0.65 0.18
(b) p = 0.2,∆− = 0.25,∆0 = 0.3, c = 0, nfix = 212
t ASS± SD G+ sel. CP n > nfix
0.2 75± 19 0.501 0.81 0.43
0.35 76± 24 0.499 0.8 0.447
0.5 79± 26 0.5 0.79 0.462
0.65 82± 26 0.5 0.75 0.429
0.8 89± 26 0.501 0.69 0.414
(c) p = 0.2,∆− = 0.5,∆0 = 0.5, c = 0, nfix = 77
Figure 5.1: Distribution of sample size using the selection rule based on estimated
eﬀect diﬀerences with c = 0; p = 0.2. Sample size recalculation is based on the eﬀect
size from the planning phase.
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t ASS± SD G+ sel. CP n > nfix
0.2 95± 38 0.817 0.81 0.08
0.35 96± 33 0.885 0.8 0.052
0.5 101± 24 0.924 0.72 0.033
0.65 111± 1 0.948 0.01 0
0.8 135± 0 0.965 0 0
(a) p = 0.7,∆− = 0,∆0 = 0.35, c = 0, nfix = 156
t ASS± SD G+ sel. CP n > nfix
0.2 85± 27 0.645 0.81 0.188
0.35 84± 30 0.69 0.8 0.188
0.5 85± 28 0.722 0.77 0.174
0.65 88± 21 0.749 0.63 0.117
0.8 95± 0 0.772 0 0
(b) p = 0.7,∆− = 0.25,∆0 = 0.425, c = 0, nfix = 106
t ASS± SD G+ sel. CP n > nfix
0.2 73± 20 0.5 0.81 0.37
0.35 71± 25 0.5 0.8 0.34
0.5 69± 25 0.501 0.77 0.292
0.65 71± 20 0.501 0.67 0.207
0.8 75± 13 0.499 0.31 0.101
(c) p = 0.7,∆− = 0.5,∆0 = 0.5, c = 0, nfix = 77
Figure 5.2: Distribution of sample size using the selection rule based on estimated
eﬀect diﬀerences with c = 0; p = 0.7. Sample size recalculation is based on the eﬀect
size from the planning phase.
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For c = 0.2 (see Figure 5.3 for p = 0.2 and Figure 5.4 for p = 0.7), properties of the
sample size distribution when comparing diﬀerent interim analysis timings are similar
as compared to the respective scenarios with c = 0. However, when using a higher
c, the probability to select G0 in the interim analysis is higher. While the sample size
distributions for G0 and G+ are very similar when using a higher c compared to scenarios
with a smaller c, the sample size distribution for G0 has a greater contribution to the
overall sample size. This behavior leads to an altered overall sample size distribution
especially for scenarios where distributions are very diﬀerent for both interim decisions,
namely scenarios with ∆− < 0.5, i.e. ∆− < ∆+. In these cases, the average sample
size is higher for the situation that the total population is selected as compared to the
situation that the subgroup is selected due to the smaller eﬀect size ∆−. For early interim
analyses, this leads to a larger overall average sample size in scenarios with ∆− < 0.5
when using a higher c. In addition, the probability Pr(n > nfix) is increased. For late
interim analysis timings, the sample size increase for a higher c is not as pronounced since
the second-stage sample size is in many cases the minimal sample size of 10. Thus, the
smallest average sample size is achieved for later interim analyses when using a higher c.
For example, in the scenario p = 0.7,∆− = 0 (see Figure 5.4a), the average sample size is
121 for t = 0.2 and therefore, considerably larger than 95, which was the value observed
in the respective scenario with c = 0. Simultaneously, the increase of the average sample
size for t = 0.8 from 135 to 140 is much smaller.
For ∆− = 0.5 (see Figure 5.3c and Figure 5.4c), sample size distributions for G0 and G+
are similar, and a higher value of c, which leads to a larger contribution of the sample
size distribution of G0 to the overall sample size, does not lead to considerable diﬀerences
between the overall sample size distributions for diﬀerent c. For example, in the scenario
p = 0.7,∆− = 0.5 (see Figure 5.4c), the average sample size for t = 0.2 is 71 using
c = 0.2, and 73 for c = 0.
To summarize, especially for the case that the eﬀect in the subgroup is larger than in
the total population, a larger c tends to shift the minimum average sample size to later
timings.
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t ASS± SD G+ sel. CP n > nfix
0.2 527± 428 0.916 0.8 0.035
0.35 676± 0 0.966 0 0
0.5 961± 0 0.985 0 0
0.65 1246± 0 0.993 0 0
0.8 1532± 0 0.997 0 0
(a) p = 0.2,∆− = 0,∆0 = 0.1, c = 0.2, nfix = 1902
t ASS± SD G+ sel. CP n > nfix
0.2 151± 72 0.5 0.81 0.22
0.35 156± 70 0.499 0.8 0.192
0.5 166± 66 0.5 0.79 0.173
0.65 175± 55 0.5 0.72 0.134
0.8 189± 36 0.5 0.4 0.073
(b) p = 0.2,∆− = 0.25,∆0 = 0.3, c = 0.2, nfix = 212
t ASS± SD G+ sel. CP n > nfix
0.2 72± 19 0.39 0.8 0.351
0.35 73± 24 0.357 0.8 0.375
0.5 72± 25 0.331 0.78 0.349
0.65 74± 22 0.308 0.72 0.283
0.8 79± 17 0.289 0.52 0.192
(c) p = 0.2,∆− = 0.5,∆0 = 0.5, c = 0.2, nfix = 77
Figure 5.3: Distribution of sample size using the selection rule based on estimated
eﬀect diﬀerences with c = 0.2; p = 0.2. Sample size recalculation is based on the eﬀect
size from the planning phase.
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t ASS± SD G+ sel. CP n > nfix
0.2 121± 52 0.382 0.8 0.252
0.35 125± 56 0.345 0.8 0.253
0.5 124± 51 0.317 0.75 0.203
0.65 129± 40 0.293 0.62 0.142
0.8 140± 21 0.273 0.17 0.056
(a) p = 0.7,∆− = 0,∆0 = 0.35, c = 0.2, nfix = 156
t ASS± SD G+ sel. CP n > nfix
0.2 94± 32 0.267 0.81 0.321
0.35 93± 37 0.205 0.8 0.307
0.5 93± 36 0.163 0.77 0.27
0.65 95± 30 0.131 0.67 0.201
0.8 101± 20 0.107 0.35 0.112
(b) p = 0.7,∆− = 0.25,∆0 = 0.425, c = 0.2, nfix = 106
t ASS± SD G+ sel. CP n > nfix
0.2 71± 21 0.198 0.8 0.346
0.35 71± 26 0.131 0.8 0.344
0.5 70± 26 0.09 0.77 0.296
0.65 71± 21 0.063 0.66 0.207
0.8 76± 13 0.045 0.3 0.106
(c) p = 0.7,∆− = 0.5,∆0 = 0.5, c = 0.2, nfix = 77
Figure 5.4: Distribution of sample size using the selection rule based on estimated
eﬀect diﬀerences with c = 0.2; p = 0.7. Sample size recalculation is based on the eﬀect
size from the planning phase.
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5.2.2.2 Using the Mean of the Eﬀect Size from the Planning Phase and the
Interim Eﬀect Estimate for Sample Size Reassessment
In this section, results are considered when the mean of the assumed eﬀect from the
planning phase and the observed eﬀect in the interim analysis is used for sample size
recalculation. Results are presented in Figure 5.5 and Figure 5.6 for c = 0 and in
the Appendix in Figure B.1 and Figure B.2 for c = 0.2, for a prevalence of p = 0.2
and p = 0.7, respectively. Comparing diﬀerent scenarios regarding the timing with
the smallest average sample size show similar behavior as compared to the strategy
where the recalculation is only based on the treatment eﬀect assumed in the planning
stage. For larger prevalence, larger ∆−, or larger c, the average sample size occurs for
later interim analysis timings. However, in comparison to the strategy where only the
assumed eﬀect from the planning stage is used for recalculation, the average sample
size and the standard deviation are higher when incorporating the observed eﬀect of
the interim analysis to recalculate the sample size. This is the case in particular for
early interim analysis timings, where the recalculated sample size is often the maximum
possible sample size if G0 is selected. For example, for p = 0.2,∆− = 0.25 (see Figure
5.5b), and a timing of 0.2, the average sample size and standard deviation is 164± 117
if the observed eﬀect from the interim analysis is incorporated, and 134± 63 if only the
assumed eﬀect from the planning phase is used for sample size recalculation. Moreover,
in the same scenario, the probability for n > nfix is increased from 0.142 (when using
only the eﬀect from the planning phase) to 0.242 (when incorporating the observed
eﬀect). For later interim analyses, the diﬀerence between sample size distributions of the
two recalculation methods become more similar. A reason for the increased standard
deviation is that the eﬀect size used for sample size calculation is a random variable and
not ﬁxed.
Therefore, early interim analysis timings should especially be avoided when incorporating
the observed eﬀect from the interim analysis to recalculate the sample size. Apart from
the situation where ∆0 is very small (see Figure 5.5a) and an early interim analysis is
favorable due to the high nfix, the average sample size and the standard deviation are
smallest for later interim analysis timings. Furthermore, the probability Pr(n > nfix) is
also smaller for later interim analysis timings. However, a very late interim analysis is
also not advantageous since it is very likely that the minimal sample size is chosen for
the second stage due to the small required conditional power.
Results for using a higher c (see Figure B.1 and Figure B.2 for c = 0.2 in the Appendix)
show similar characteristics as described previously when increasing c from 0 to 0.2:
Obviously, the probability to select G0 increases and moreover, the average sample size
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is especially inﬂated for early timings. This means the smallest average sample size is
shifted to later timings.
To summarize, an interim analysis timing around t = 0.5 is suitable in most situations,
although diﬀerent prevalences and eﬀect sizes inﬂuence the sample size distributions and
should be taken into account when determining the timing of the interim analysis.
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t ASS± SD G+ sel. CP n > nfix
0.2 417± 113 0.997 0.76 0.001
0.35 676± 0 > 0.999 0 0
0.5 961± 0 > 0.999 0 0
0.65 1246± 0 > 0.999 0 0
0.8 1532± 0 > 0.999 0 0
(a) p = 0.2,∆− = 0,∆0 = 0.1, c = 0, nfix = 1902
t ASS± SD G+ sel. CP n > nfix
0.2 164± 117 0.677 0.89 0.242
0.35 160± 92 0.729 0.83 0.184
0.5 168± 75 0.766 0.78 0.166
0.65 180± 59 0.797 0.68 0.156
0.8 200± 49 0.821 0.52 0.171
(b) p = 0.2,∆− = 0.25,∆0 = 0.3, c = 0, nfix = 212
t ASS± SD G+ sel. CP n > nfix
0.2 89± 47 0.499 0.95 0.504
0.35 85± 41 0.5 0.9 0.458
0.5 83± 37 0.5 0.85 0.426
0.65 85± 32 0.501 0.79 0.396
0.8 90± 29 0.501 0.72 0.393
(c) p = 0.2,∆− = 0.5,∆0 = 0.5, c = 0, nfix = 77
Figure 5.5: Distribution of sample size using the selection rule based on estimated
eﬀect diﬀerences with c = 0; p = 0.2. Sample size recalculation is based on the mean of
the eﬀect size from the planning phase and the interim eﬀect estimate.
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t ASS± SD G+ sel. CP n > nfix
0.2 115± 79 0.817 0.82 0.211
0.35 105± 58 0.884 0.75 0.132
0.5 104± 38 0.924 0.6 0.07
0.65 111± 0 0.949 0 0
0.8 135± 0 0.965 0 0
(a) p = 0.7,∆− = 0,∆0 = 0.35, c = 0, nfix = 156
t ASS± SD G+ sel. CP n > nfix
0.2 102± 62 0.647 0.85 0.36
0.35 93± 52 0.689 0.79 0.282
0.5 89± 42 0.722 0.7 0.207
0.65 90± 28 0.749 0.48 0.118
0.8 95± 0 0.772 0 0
(b) p = 0.7,∆− = 0.25,∆0 = 0.425, c = 0, nfix = 106
t ASS± SD G+ sel. CP n > nfix
0.2 85± 46 0.5 0.87 0.458
0.35 78± 41 0.501 0.81 0.382
0.5 73± 35 0.501 0.72 0.293
0.65 72± 26 0.499 0.55 0.192
0.8 76± 15 0.5 0.15 0.08
(c) p = 0.7,∆− = 0.5,∆0 = 0.5, c = 0, nfix = 77
Figure 5.6: Distribution of sample size using the selection rule based on estimated
eﬀect diﬀerences with c = 0; p = 0.7. Sample size recalculation is based on the mean of
the eﬀect size from the planning phase and the interim eﬀect estimate.
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5.2.3 Selection Rule Based on Absolute Eﬀect Estimates
In this section, results using the selection rule based on absolute eﬀect estimates are
presented. This selection rule additionally includes the option to stop for futility (shown
in yellow color) and the option to continue with both populations (shown in green color).
The tables to the right of the ﬁgures contain the same statistics as in the previous
subsection showing results for the selection rule based on estimated eﬀect diﬀerences,
however, the probability is given for a correct selection instead of the probability to
select G+.
5.2.3.1 Using the Eﬀect Size from the Planning Phase for Sample Size Re-
assessment
Firstly, results are considered in case the eﬀect size from the planning phase is used for
sample size reassessment. Figure 5.7 (p = 0.2) and Figure 5.8 (p = 0.7) depict results
for c+ = 0.1. In the scenario showing distributions for ∆0 = 0.1 and p = 0.2 (Figure
5.7a), the subgroup is selected with a probability > 99%, while with a probability of
50% the total population is selected as well, and the co-primary analysis is conducted.
As observed for the selection rule based on estimated eﬀect diﬀerences, the smallest
average sample size occurs for early interim timings if the diﬀerence between ∆+ and
∆0 is high. However, the sample size is clearly increased if both populations are selected
at t = 0.2. For later interim analyses (t > 0.35) the sample size in the second stage
is always the minimal sample size since the conditional power is 0. Practically, the
scenarios with late interim analyses are hardly comparable since the power is larger than
80% (86.5%, 97.8%, 99.8%, > 99.9% for t = 0.35, 0.5, 0.65, 0.8).
For higher ∆− (Figure 5.7 b and c), interim analysis timings around t = 0.5 lead to the
smallest average sample size. Moreover, if both populations are selected, the sample size
is greatly increased for early interim analysis timings in settings with a small prevalence.
The reason is that the maximum of the sample size calculated for the total population
and the sample size calculated for the subgroup divided by the prevalence is used, of
which the latter can become relatively large for small prevalences. Consequently, also
Pr(n > nfix) is high, especially if the selection of both populations is likely, as is the
case for ∆− = 0.5. In this situation, the maximum possible sample size is used with a
high probability for early timings, and for later timings, the sample size in the second
stage is always the smallest possible sample size.
In scenarios with a higher prevalence (Figure 5.8), the sample size's standard deviation
is smaller since the sample size distributions are more similar for diﬀerent decisions. The
timing with the smallest average sample size is still around 0.5 for scenarios with ∆− > 0.
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For ∆− = 0, the smallest average sample size is observed for t = 0.35. Hence, for small
and high prevalence, the smallest average sample size is achieved by later timings for
higher ∆−.
In each scenario, the correct interim decision is to select both populations, while only
in the scenario with p = 0.2 and ∆0 = 0.1, only the subgroup should be selected.
As expected, the probability for making a correct decision increases with increasing t.
However, in the considered scenarios, a relatively high probability is already achieved for
a timing around 0.5 and increases only slightly for higher t.
Overall, early interim analyses lead to a large standard deviation of the sample size
and the probability to require a sample size that is larger than the sample size in the
ﬁxed design is relatively high in most scenarios. Late interim analyses can be deemed
meaningless since the sample size of the ﬁrst stage is already suﬃcient in many cases and
the conditional power required to achieve an overall power of at least 80% is 0. Hence,
an interim analysis after approximately half of the sample size that was calculated for
a ﬁxed setting seems reasonable in most situations. Only if the eﬀect in the overall
population is very small, early interim analyses in relation to the sample size in the ﬁxed
design, which is relatively large in this setting, are advantageous.
Results for a higher threshold c+ are presented in Figure 5.9 for p = 0.2 and Figure
5.10 for p = 0.7. In this case, the probability to stop for futility and to select only
G0 is higher. Due to the higher probability for a futility stop, the conditional power is
generally increased which leads to a higher average sample size compared to scenarios
with a smaller c+. This is especially pronounced for early interim analyses making early
timings even less advisable. However, an exception is the scenario shown in Figure 5.9c,
where the eﬀects are equal in both populations and the prevalence is small. In this case,
the average sample size is sometimes smaller compared to the scenario with c+ = 0.1. In
this scenario, both populations are selected with a high probability which often leads to
the maximum possible sample size. Nevertheless, comparisons of the characteristics of
the sample size distributions for diﬀerent interim timings are very similar to distributions
with a smaller c+.
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t ASS± SD corr. sel. CP n > nfix
0.2 668± 300 0.494 0.59 0
0.35 696± 20 0.5 0 0
0.5 981± 20 0.5 0 0
0.65 1266± 20 0.5 0 0
0.8 1552± 20 0.5 0 0
(a) p = 0.2,∆− = 0,∆0 = 0.1, c+ = 0.1, nfix = 1902
t ASS± SD corr. sel. CP n > nfix
0.2 204± 88 0.692 0.67 0.472
0.35 193± 74 0.791 0.56 0.349
0.5 188± 57 0.852 0.4 0.24
0.65 188± 19 0.895 0.08 0.058
0.8 217± 21 0.926 0 0.926
(b) p = 0.2,∆− = 0.25,∆0 = 0.3, c+ = 0.1, nfix = 212
t ASS± SD corr. sel. CP n > nfix
0.2 111± 52 0.636 0.61 0.629
0.35 102± 46 0.715 0.4 0.579
0.5 87± 27 0.767 0.12 0.767
0.65 92± 16 0.805 0 0.805
0.8 105± 15 0.834 0 0.834
(c) p = 0.2,∆− = 0.5,∆0 = 0.5, c+ = 0.1, nfix = 77
Figure 5.7: Distribution of sample size using the selection rule based on absolute eﬀect
estimates with c+ = 0.1; p = 0.2. Sample size recalculation is based on the eﬀect size
from the planning phase.
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t ASS± SD corr. sel. CP n > nfix
0.2 108± 34 0.818 0.72 0.065
0.35 104± 30 0.895 0.63 0.067
0.5 105± 21 0.937 0.47 0.04
0.65 115± 1 0.961 0 0
0.8 139± 1 0.975 0 0
(a) p = 0.7,∆− = 0,∆0 = 0.35, c+ = 0.1, nfix = 156
t ASS± SD corr. sel. CP n > nfix
0.2 93± 30 0.808 0.8 0.365
0.35 88± 27 0.89 0.72 0.269
0.5 85± 23 0.934 0.6 0.197
0.65 88± 13 0.96 0.34 0.102
0.8 99± 1 0.975 0 0
(b) p = 0.7,∆− = 0.25,∆0 = 0.425, c+ = 0.1, nfix = 106
t ASS± SD corr. sel. CP n > nfix
0.2 78± 30 0.788 0.76 0.591
0.35 72± 25 0.87 0.66 0.408
0.5 69± 21 0.918 0.53 0.296
0.65 70± 13 0.946 0.28 0.163
0.8 76± 2 0.964 0 0
(c) p = 0.7,∆− = 0.5,∆0 = 0.5, c+ = 0.1, nfix = 77
Figure 5.8: Distribution of sample size using the selection rule based on absolute eﬀect
estimates with c+ = 0.1; p = 0.7. Sample size recalculation is based on the eﬀect size
from the planning phase.
CHAPTER 5. DESIGN WITH SAMPLE SIZE REASSESSMENT 62
t ASS± SD corr. sel. CP n > nfix
0.2 823± 455 0.413 0.74 0
0.35 695± 21 0.457 0 0
0.5 981± 20 0.478 0 0
0.65 1266± 20 0.489 0 0
0.8 1552± 20 0.494 0 0
(a) p = 0.2,∆− = 0,∆0 = 0.1, c+ = 0.3, nfix = 1902
t ASS± SD corr. sel. CP n > nfix
0.2 223± 98 0.589 0.77 0.2
0.35 198± 72 0.663 0.67 0.064
0.5 191± 55 0.713 0.57 0.019
0.65 192± 31 0.75 0.37 0
0.8 211± 17 0.781 0 0
(b) p = 0.2,∆− = 0.25,∆0 = 0.3, c+ = 0.3, nfix = 212
t ASS± SD corr. sel. CP n > nfix
0.2 108± 52 0.558 0.71 0.6
0.35 105± 48 0.609 0.58 0.597
0.5 99± 41 0.642 0.41 0.666
0.65 87± 19 0.667 0 0.667
0.8 99± 19 0.688 0 0.688
(c) p = 0.2,∆− = 0.5,∆0 = 0.5, c+ = 0.3, nfix = 77
Figure 5.9: Distribution of sample size using the selection rule based on absolute eﬀect
estimates with c+ = 0.3; p = 0.2. Sample size recalculation is based on the eﬀect size
from the planning phase.
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t ASS± SD corr. sel. CP n > nfix
0.2 126± 48 0.717 0.82 0.304
0.35 113± 37 0.793 0.71 0.151
0.5 110± 27 0.843 0.57 0.092
0.65 115± 3 0.877 0.08 0
0.8 138± 2 0.903 0 0
(a) p = 0.7,∆− = 0,∆0 = 0.35, c+ = 0.3, nfix = 156
t ASS± SD corr. sel. CP n > nfix
0.2 103± 38 0.69 0.87 0.582
0.35 90± 28 0.757 0.77 0.306
0.5 87± 24 0.802 0.68 0.211
0.65 89± 15 0.835 0.47 0.103
0.8 98± 2 0.861 0 0
(b) p = 0.7,∆− = 0.25,∆0 = 0.425, c+ = 0.3, nfix = 106
t ASS± SD corr. sel. CP n > nfix
0.2 83± 31 0.668 0.83 0.708
0.35 72± 22 0.726 0.73 0.448
0.5 69± 18 0.767 0.64 0.328
0.65 70± 12 0.799 0.47 0.195
0.8 75± 2 0.823 0 0
(c) p = 0.7,∆− = 0.5,∆0 = 0.5, c+ = 0.3, nfix = 77
Figure 5.10: Distribution of sample size using the selection rule based on absolute
eﬀect estimates with c+ = 0.3; p = 0.7. Sample size recalculation is based on the eﬀect
size from the planning phase.
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5.2.3.2 Using the Mean of the Eﬀect Size from the Planning Phase and the
Interim Eﬀect Estimate for Sample Size Reassessment
In this section, the mean of the assumed eﬀect size from the planning phase and the
interim eﬀect estimate is used for sample size reassessment. Results are presented in
Figure 5.11 and Figure 5.12 for c+ = 0.1 and in the Appendix in Figure B.3 and Figure
B.4 for c+ = 0.3, for a prevalence of p = 0.2 and p = 0.7, respectively. As already
observed for the other selection rule, when incorporating the observed interim eﬀect for
sample size reassessment, the standard deviation of the sample size is increased in many
scenarios in comparison to a sample size recalculation which is only based on the eﬀect
size assumed in the planning stage. Furthermore, the maximum possible sample size
is reached more often. This is especially pronounced for early interim analyses where
the variability of the observed eﬀect is higher due to the smaller sample size in the ﬁrst
stage. An exception is the scenario shown in Figure 5.11c. Here, the standard deviation
is similar in comparison to the situation where only the eﬀect assumed in the planning
phase is used. In this case, the maximum sample size was also reached quite frequently
when only using the eﬀect from the planning phase.
The incorporation of the observed interim eﬀect leads to the smallest or largest possible
sample size in many cases. Despite the increased variance for early interim analysis
timings, the timing with the smallest sample size is still around 0.5 for most of the
considered scenarios. Only for the scenario with p = 0.2 and ∆− = 0 (Figure 5.11a), in
which the sample size in the ﬁxed design is very high, the sample size of the ﬁrst stage is
already suﬃcient for early timings in many cases and the reassessed sample size is mostly
very small. Hence, the sample size increases with increasing interim analysis timing in
this case. When using a higher c+ (see Figure B.3 and Figure B.4 in the Appendix),
characteristics are very similar. However, the probability to select G+ is smaller and
therefore, the probability to stop for futility and the probability to only select G0 is
higher. For early timings, the average sample size is increased when using a larger c+ in
scenarios with ∆+ < 0.5. Here, the maximum sample size is often reached in case only
G0 is selected. Therefore, when using a higher c+, the smallest average sample size tends
to be present for later interim analysis timings.
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t ASS± SD corr. sel. CP n > nfix
0.2 568± 217 0.494 0.55 0
0.35 696± 20 0.499 0 0
0.5 981± 20 0.5 0 0
0.65 1266± 20 0.499 0 0
0.8 1552± 20 0.5 0 0
(a) p = 0.2,∆− = 0,∆0 = 0.1, c+ = 0.1, nfix = 1902
t ASS± SD corr. sel. CP n > nfix
0.2 224± 127 0.693 0.71 0.462
0.35 204± 105 0.789 0.49 0.351
0.5 194± 80 0.854 0.28 0.235
0.65 188± 24 0.896 0.03 0.05
0.8 217± 11 0.925 0 0.925
(b) p = 0.2,∆− = 0.25,∆0 = 0.3, c+ = 0.1, nfix = 212
t ASS± SD corr. sel. CP n > nfix
0.2 98± 49 0.636 0.64 0.576
0.35 94± 41 0.715 0.35 0.457
0.5 87± 29 0.767 0.07 0.768
0.65 92± 16 0.805 0 0.805
0.8 105± 15 0.834 0 0.834
(c) p = 0.2,∆− = 0.5,∆0 = 0.5, c+ = 0.1, nfix = 77
Figure 5.11: Distribution of sample size using the selection rule based on absolute
eﬀect estimates with c+ = 0.1; p = 0.2. Sample size recalculation is based on the mean
of the eﬀect size from the planning phase and the interim eﬀect estimate.
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t ASS± SD corr. sel. CP n > nfix
0.2 127± 75 0.818 0.72 0.295
0.35 113± 55 0.895 0.55 0.19
0.5 107± 31 0.936 0.33 0.089
0.65 115± 1 0.961 0 0
0.8 139± 1 0.975 0 0
(a) p = 0.7,∆− = 0,∆0 = 0.35, c+ = 0.1, nfix = 156
t ASS± SD corr. sel. CP n > nfix
0.2 111± 64 0.808 0.8 0.464
0.35 97± 52 0.89 0.63 0.335
0.5 90± 38 0.934 0.44 0.216
0.65 90± 19 0.96 0.17 0.097
0.8 99± 1 0.976 0 0
(b) p = 0.7,∆− = 0.25,∆0 = 0.425, c+ = 0.1, nfix = 106
t ASS± SD corr. sel. CP n > nfix
0.2 90± 49 0.788 0.8 0.54
0.35 78± 41 0.87 0.59 0.402
0.5 72± 32 0.917 0.39 0.279
0.65 71± 19 0.946 0.14 0.143
0.8 76± 2 0.964 0 0
(c) p = 0.7,∆− = 0.5,∆0 = 0.5, c+ = 0.1, nfix = 77
Figure 5.12: Distribution of sample size using the selection rule based on absolute
eﬀect estimates with c+ = 0.1; p = 0.7. Sample size recalculation is based on the mean
of the eﬀect size from the planning phase and the interim eﬀect estimate.
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5.3 Clinical Trial Example
In this section, the choice of the interim analysis timing is investigated for parameters
observed in the MILLY trial, which was introduced in Section 4.3. In Figure 5.13 and
5.14, sample size distributions are depicted for the selection rule based on estimated
eﬀect diﬀerences with c = 0.2. In Figure 5.13, the subgroup is deﬁned by high and
low periostin levels yielding the eﬀect sizes ∆per+ = 0.43 and ∆per− = 0.08. With a
prevalence of p = 0.5, the eﬀect size in the total patient population results in ∆0 =
0.255. Therefore, using c = 0.2, the correct decision is to select the total population
as target population. When using the eﬀect size from the planning phase for sample
size reassessment (see Figure 5.13a), the average sample size is slightly increasing with
increasing interim analysis timing. Regarding the smallest average sample size, an early
interim analysis would be sensible. In contrast, the standard deviation of the sample
size decreases for later timings. Especially for early timings, the sample size can be very
high if G0 is selected, and the probability Pr(n > nfix) is largest.
When recalculating the sample size using the mean of the eﬀect size from the planning
phase and the interim eﬀect estimate (see Figure 5.13b), the standard deviation for early
interim analyses is clearly increased and also Pr(n > nfix) is higher. In this case, the
sample size reaches often the maximum possible sample size if G0 is selected suggesting
that a later interim analysis might be more advantageous. In addition, the average
sample size is smallest for a timing around t = 0.5.
A similar picture is found for the subgroup deﬁned by high and low Th2 level with eﬀect
sizes ∆Th2+ = 0.34 and ∆Th2− = 0.25 (see Figure 5.14). However, the total population
is selected with a higher probability, and when using the eﬀect size from the planning
phase for sample size reassessment, the average sample size is more similar for diﬀerent
interim analysis timings. When including the interim eﬀect estimate for sample size
recalculation, later timings are more advantageous in terms of a smaller average sample
size, smaller standard deviation, larger probability to select the correct population G0
and smaller probability Pr(n > nfix).
Sample size distributions for the selection rule based on absolute eﬀect estimates with
c0 = 0.1 and c+ = 0.3 are presented in Figure 5.15 and Figure 5.16. For subgroups
deﬁned by periostin level (∆per+ = 0.43, ∆per− = 0.08), median and mean of the sample
size are smallest for a timing around t = 0.5 irrespective of whether or not the observed
eﬀect from the interim analysis is incorporated in sample size recalculation. Moreover,
the standard deviation at t = 0.5 is only approximately half the standard deviation for
a timing at 0.2, and Pr(n > nfix) is considerably reduced, which implies that a timing
around 0.5 is appropriate in this situation. If the eﬀects in both subgroups are more simi-
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lar, as is the case when subgroups are deﬁned by Th2 level (∆Th2+ = 0.34, ∆Th2− = 0.25),
an interim analysis conducted at around t = 0.65 yields the smallest average sample size.
t ASS± SD G+ sel. CP n > nfix
0.2 208± 105 0.447 0.80 0.231
0.35 217± 107 0.429 0.80 0.222
0.5 220± 94 0.415 0.75 0.176
0.65 230± 70 0.404 0.59 0.112
0.8 244± 0 0.394 0 0
(a) Using the eﬀect size from the planning phase for sample size reassessment
t ASS± SD G+ sel. CP n > nfix
0.2 250± 180 0.447 0.86 0.306
0.35 239± 156 0.429 0.8 0.255
0.5 231± 127 0.415 0.7 0.193
0.65 234± 89 0.404 0.47 0.114
0.8 244± 0 0.394 0 0
(b) Using the mean of the eﬀect size from the planning phase and the interim eﬀect
estimate for sample size reassessment
Figure 5.13: Distribution of sample size using the selection rule based on estimated
eﬀect diﬀerences with c = 0.2. Subgroups deﬁned by periostin level (∆per+ = 0.43,
∆per− = 0.08); nfix = 293.
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t ASS± SD G+ sel. CP n > nfix
0.2 195± 64 0.234 0.8 0.321
0.35 196± 77 0.169 0.8 0.326
0.5 197± 80 0.126 0.79 0.307
0.65 199± 73 0.096 0.73 0.247
0.8 208± 57 0.074 0.53 0.168
(a) Using the eﬀect size from the planning phase for sample size reassessment
t ASS± SD G+ sel. CP n > nfix
0.2 235± 136 0.234 0.87 0.443
0.35 220± 123 0.169 0.81 0.384
0.5 210± 109 0.126 0.75 0.322
0.65 204± 89 0.096 0.64 0.242
0.8 210± 65 0.074 0.39 0.154
(b) Using the mean of the eﬀect size from the planning phase and the interim eﬀect
estimate for sample size reassessment
Figure 5.14: Distribution of sample size using the selection rule based on estimated
eﬀect diﬀerences with c = 0.2. Subgroups deﬁned by Th2 level (∆Th2+ = 0.34, ∆Th2− =
0.25); nfix = 219.
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t ASS± SD corr. sel. CP n > nfix
0.2 250± 101 0.638 0.86 0.406
0.35 216± 72 0.709 0.75 0.171
0.5 207± 54 0.760 0.63 0.102
0.65 214± 18 0.798 0.29 0.007
0.8 252± 5 0.828 0 0
(a) Using the eﬀect size from the planning phase for sample size reassessment
t ASS± SD corr. sel. CP n > nfix
0.2 282± 167 0.638 0.90 0.414
0.35 234± 121 0.709 0.73 0.245
0.5 216± 82 0.760 0.56 0.151
0.65 215± 23 0.798 0.2 0.029
0.8 252± 5 0.828 0 0
(b) Using the mean of the eﬀect size from the planning phase and the interim eﬀect
estimate for sample size reassessment
Figure 5.15: Distribution of sample size using the selection rule based on absolute
eﬀect estimates with c+ = 0.3. Subgroups deﬁned by periostin level (∆per+ = 0.43,
∆per− = 0.08); nfix = 293.
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t ASS± SD corr. sel. CP n > nfix
0.2 267± 111 0.531 0.9 0.781
0.35 216± 70 0.560 0.81 0.535
0.5 199± 57 0.578 0.75 0.379
0.65 194± 46 0.592 0.67 0.250
0.8 202± 31 0.603 0.43 0.115
(a) Using the eﬀect size from the planning phase for sample size re- assessment
t ASS± SD corr. sel. CP n > nfix
0.2 277± 141 0.531 0.95 0.651
0.35 222± 105 0.560 0.80 0.455
0.5 204± 86 0.578 0.70 0.337
0.65 196± 67 0.592 0.57 0.203
0.8 204± 41 0.603 0.28 0.101
(b) Using the mean of the eﬀect size from the planning phase and the interim eﬀect
estimate for sample size reassessment
Figure 5.16: Distribution of sample size using the selection rule based on absolute eﬀect
estimates with c+ = 0.3. Subgroups deﬁned by Th2 level (∆Th2+ = 0.34, ∆Th2− = 0.25);
nfix = 219.
CHAPTER 5. DESIGN WITH SAMPLE SIZE REASSESSMENT 72
5.4 Chapter Summary
In this chapter, the impact of the interim analysis timing was investigated for an adaptive
enrichment design with sample size recalculation based on conditional power arguments.
Sample size distributions were simulated for diﬀerent interim analysis timings and char-
acteristics were compared for diﬀerent prevalences, eﬀect sizes and selection rules (based
on the diﬀerence between eﬀect estimates, and based on absolute eﬀect estimates). Fur-
thermore, two diﬀerent methods to recalculate the sample size were considered (choosing
either the assumed eﬀect from the planning phase, or the mean of the eﬀect from the
planning phase and the observed interim eﬀect).
In many situations, an interim analysis at t = 0.5 shows good properties as the average
sample size is small and the standard deviation of the sample size is reduced in compar-
ison to earlier timings. The probability to make a correct interim decision is obviously
higher than for earlier timings. Furthermore, for later interim analysis timings, the re-
quired sample size in the ﬁrst stage is very small, since an overall power of 80% is almost
or already reached with the observations from the ﬁrst stage. Only in case of very small
∆0 (equivalent to small ∆− and small prevalence), early timings are more advantageous.
In this case, nfix is very large and an early interim analysis already includes many ob-
servations, which leads to the selection of the subgroup with a high probability. Since
the eﬀect in the subgroup is substantially higher than in the total population for which
nfix was calculated, a much smaller sample size is needed.
The two diﬀerent classes of selection rules (selection rule based on estimated eﬀect dif-
ferences and selection rule based on absolute eﬀect estimates) do not lead to substantial
diﬀerences as observed for the setting with a ﬁxed sample size investigated in the preced-
ing chapter. However, when using the selection rule based on absolute eﬀect estimates,
especially early timings lead to a larger average sample size, where a high sample size is
mainly used if the co-primary analysis is selected. Therefore, when using the selection
rule based on absolute eﬀect estimates, an interim analysis timing around t = 0.5 is sen-
sible in most of the scenarios. When using the selection rule based on estimated eﬀect
diﬀerences, earlier timings might lead to a smaller average sample size, especially if the
eﬀect in G0 is smaller than in G+. However, due to an often higher standard deviation
and higher probability for n > nfix, the beneﬁt of conducting an early interim analysis
is questionable.
Moreover, two diﬀerent methods to specify the assumed eﬀect were considered which
also led to diﬀerences between sample size distributions. In comparison to the procedure
using the eﬀect size from the planning phase, the method that also incorporates the
observed eﬀect from the interim analysis tends to lead to a higher average sample size
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and standard deviation, especially for early interim analysis timings. This means, if the
observed interim eﬀect is used for sample size reassessment, particularly early timings
should be avoided due to the higher uncertainty of eﬀect estimation for a smaller sample
size.
It should be noted that in the simulation studies, the assumed eﬀect in the planning
phase was considered to be equal to the true eﬀect. Results might be diﬀerent if the
assumed eﬀect in the planning phase is not the true eﬀect and a better estimation can be
achieved when incorporating the observed interim eﬀect. Furthermore, the sample size
of the ﬁxed design depends on the assumed eﬀect in the planning phase and therefore,
also the timing of the interim analysis. If a diﬀerent eﬀect in the planning phase is
assumed, the calculated sample size of the ﬁxed design and thus also the timing of the
interim analysis would be diﬀerent. This means that if the assumed eﬀect is too high,
nfix is smaller and, thereby, the sample size in the ﬁrst stage is smaller for the same t.
Assuming a too small eﬀect will result in a higher nfix and a larger ﬁrst-stage sample
size for the same t.
Chapter 6
Discussion
Adaptive enrichment designs have become more popular in recent years due to an in-
creased interest in targeted therapies. The methodology oﬀers a useful tool for selecting
the patient population with the most promising treatment eﬀect and testing for eﬃcacy
in a single trial. However, to proﬁt from the advantages of this design, a careful choice
of the interim analysis timing is crucial as this thesis shows.
In this thesis, the impact of the interim analysis timings was investigated for diﬀerent
settings and for two diﬀerent classes of selection rules using simulation studies. In the
ﬁrst part, a ﬁxed overall sample size is considered where the impact of diﬀerent timings
on the power was investigated. Although the initially proposed adaptive enrichment
design assumed a ﬁxed, prespeciﬁed sample size of the second stage (see, e.g., Wang
et al., 2007; Brannath et al., 2009; Jenkins et al., 2011), adaptive designs in general
oﬀer the possibility to reassess the sample size. This might be very useful since, in
general, assumptions in the planning phase are uncertain. For example, speciﬁcation of
the treatment eﬀects in diﬀerent populations might be vague, and in the planning phase
it is not known for which population the conﬁrmatory proof of eﬃcacy will be conducted
at the end of the trial. Therefore, adaptive enrichment designs including a sample size
reassessment for the second stage are considered in the second part of the thesis. In
this case, the overall sample size distribution is compared for diﬀerent interim analysis
timings.
When the overall sample size is ﬁxed, results showed that the timing of the interim
analysis has indeed an impact on the power of the study. Of course, the degree of
inﬂuence depends on the speciﬁc scenario as diﬀerent selection rules, the eﬀect sizes, and
the prevalences lead to diﬀerent power characteristics.
In case the power maximum occurs at a medium timing and not at an extreme timing, it
is sensible to use the power maximum to deﬁne the interim analysis timing. In this case,
the sample size in the ﬁrst stage is not too small and the correct target population can
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be selected with a reasonable certainty, and on the other hand, the remaining number
of patients for the second stage is large enough to have a decisive inﬂuence on the ﬁnal
test statistic and hence, on the power of the study.
When using the selection rule based on estimated eﬀect diﬀerences, where either the sub-
group or the total population is selected, the power maximum is achieved at extremely
early timings if treatment eﬀects are similar for the subgroup and the total population.
If one is solely interested in achieving a high power, a very early conduct of the in-
terim analysis would be advantageous. However, in this case, the choice of the target
population is more or less random which is not the intention when using an adaptive
enrichment design. This characteristic also indicates that the use of the selection rule
based on the diﬀerence between the eﬀect in the subgroup and the total population may
be inappropriate under certain conditions. If the treatment eﬀect in the total population
is smaller than the treatment eﬀect in the subgroup by a certain amount but the eﬀect
is still relevant, it would be desirable to select both populations.
The selection rule based on absolute eﬀect estimates that was considered includes two
further options, namely the possibility to test for eﬃcacy in the subgroup and the total
population in the ﬁnal analysis in case both treatment eﬀects are promising, and to stop
for futility in case the interim analysis shows futile eﬀect sizes. The latter option leads
to a power loss if the interim analysis is conducted early. This means, early interim
analyses cannot be recommended in general using this selection rule. Nevertheless, the
futility stop is a useful option to prevent further patients from receiving a potentially
ineﬃcient treatment. Whether later timings show a higher or smaller power depends
on the scenario. However, in many cases, power is relatively constant after half of the
patients are enrolled, which means that a timing of t = 0.5 has in general no considerable
disadvantages in comparison to later timings.
Overall, for a prespeciﬁed, ﬁxed sample size, the selection rule, eﬀect sizes, and also
the prevalence have an impact on the power characteristics for diﬀerent interim analysis
timings. However, not only the power should be considered, especially, if the power is
maximal for extremely early or late timings. For example, it should be taken into account
that the probability for a false decision is increased for an early interim analysis timing.
On the other hand, for late timings, it is not possible anymore to inﬂuence the conduct
of the study to a meaningful extent. Furthermore, if the subgroup is selected, the ﬁrst
stage should not be too large since the number of patients from the complementary group
should be as small as possible due to ethical and ﬁnancial reasons.
If not only the target population is selected in the interim analysis but also the sample
size for the second stage is reassessed based on the observed interim results, diﬀerent
selection rules and eﬀect sizes do not lead to substantial diﬀerences when comparing the
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sample size distribution for diﬀerent interim analysis timings. In many scenarios, the
average sample size is smallest for early to medium timings. However, also the standard
deviation of the second-stage sample size is in general high for early timings. For late
timings, it was observed that the sample size in the ﬁrst stage was already suﬃcient in
many cases and hence, the number of patients in the second stage is the smallest possible
sample size which indicates that a late interim analysis is not sensible.
Nevertheless, the sample size distribution depends on the scenario, i.e. the eﬀect sizes,
prevalence and the applied selection rule, and therefore, the interim analysis timing
should be selected individually for each situation.
Furthermore, it makes a diﬀerence how the assumed eﬀect for sample size recalculation
is chosen. In this thesis, two diﬀerent approaches were considered: using the assumed
eﬀect from the planning phase, and using the mean of the assumed eﬀect from the
planning phase and the observed interim eﬀect. The comparison of both approaches
has shown, particularly for early interim analyses, that the average sample size and
especially the standard deviation of the sample size is increased if the observed eﬀect
from the interim analysis is included. The large variability for early interim analyses in
case the observed interim eﬀect is incorporated was also shown by Bauer and Koenig
(2006) who investigated the impact of the interim analysis timing for common adaptive
designs without subgroup selection. Furthermore, the high standard deviation relates in
many cases to a high probability that the maximum possible sample size is used, which
implies that the upper limit for sample size should be chosen carefully.
The described ﬁndings also suggest that it might be advantageous to use the assumed
eﬀect from the planning phase for sample size recalculation to prevent extremely large
sample sizes. However, it has to be noted that in the conducted simulation studies the
used eﬀect from the planning phase was assumed to be the true eﬀect, and results might
be diﬀerent if this assumption is not true, especially if the assumed eﬀect in the planning
phase diﬀers considerably from the true eﬀect. If there is high uncertainty about the
treatment eﬀect and the observed eﬀect from the planning phase shall be used for sample
size recalculation in addition to conditioning on the observed test statistic, early interim
analyses should be avoided to obtain more precise treatment eﬀect estimates.
Anyhow, there are some further limitations. At ﬁrst, simulations were used to investigate
characteristics for diﬀerent interim analysis timings, and no analytical formula could be
derived to specify, for example, the power maximum depending on the eﬀect size, the
prevalence and the selection rule. Even if the simulated scenarios give a comprehensive
insight to the impact of diﬀerent interim analysis timings, no general rules could be
established.
Moreover, only normally distributed endpoints were considered, and, for example, time-
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to-event endpoints, which are often considered in oncological trials, were not investigated.
However, it is reasonable to assume that results do not considerably diﬀer.
For sake of simplicity, some further assumptions were made. For example, it is assumed
that the classiﬁcation of a patient to the subgroup or the complementary group is correct
with a probability of 100%. In practice, this perfection might not be given and incorrect
assignment might occur which leads to biased eﬀect estimates for the diﬀerent popula-
tions. In addition, the prevalence of the subgroup was assumed to be ﬁx. Furthermore,
known standard deviation was assumed and the z-test was used, which is not practical.
However, results should be similar when using, for example, a t-test in case the standard
deviation is not known.
To conclude, ﬁndings of this thesis show that regardless of whether the overall sample
size is ﬁxed in advance, or the sample size of the second stage is recalculated, the interim
analysis timing has to be chosen carefully for the speciﬁc design features and param-
eter assumptions at hand since no general rules could be established and no speciﬁc
timing of the interim analysis can be recommended that uniformly ﬁts to all scenarios.
Instead, sensitivity analyses taking the speciﬁc design features into account should be
conducted in the planning stage of a trial to determine the appropriate timings of an
interim analysis.
Chapter 7
Summary
English
This thesis deals with adaptive enrichment designs, which are especially applied in the
development of targeted therapies. These designs are devised for the situation in which
a higher treatment eﬀect is assumed in a speciﬁc subgroup but eﬃcacy cannot be ruled
out in the total population. The idea of this two-stage study design is to decide in an
interim analysis based on observed treatment eﬀects whether the subgroup or the total
population is selected for enrichment in the second stage of the trial, and for which
population a test for eﬃcacy is conducted in the ﬁnal analysis.
The aim of this thesis is to investigate the impact of the interim analysis timing on the
power of the study for a normally distributed endpoint. Diﬀerent eﬀect sizes and preva-
lences of the subgroup, as well as two diﬀerent classes of selection rules were considered.
The ﬁrst selection rule is based on the comparison of the estimated eﬀect diﬀerence be-
tween the subgroup and the total population with a prespeciﬁed threshold value, and the
subgroup or the total population is selected, respectively. The second selection rule that
is considered is based on the absolute eﬀect estimates from the subgroup and the total
population, each compared to a prespeciﬁed threshold value. Possible options of this
selection rule are to select either the subgroup, the total population, both populations,
or no population. The latter option leads to termination of the study (stop for futility)
without rejecting any hypothesis.
In the ﬁrst part, the impact of the interim timing on the power of the study is investigated
for a ﬁxed overall sample size. Analytical derivation of the power was not possible, and,
as a consequence, power was determined using simulation studies. Results showed that
the interim timing inﬂuences the power of the study to a varying degree for diﬀerent
scenarios. In particular, the chosen selection rule leads to diﬀerent power characteristics
as a function of interim analysis timing. For example, the power is rather small in case
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the second selection rule, that is based on absolute eﬀect estimates, is used, which can be
explained by the incorporated option to stop for futility. In contrast, for the ﬁrst selection
rule, which is based on the diﬀerence between the eﬀect estimates, the smallest power
was achieved for early timings in many scenarios. Additionally, the power maximum
depends on the eﬀect sizes and the prevalence of the subgroup. This shows that there is
no particular interim timing which is optimal with regard to the power in every scenario.
When choosing the interim analysis timing, the assumed eﬀect sizes, the prevalence, and
the chosen selection rule should be taken into account.
In the second part, an adaptive enrichment design including sample size recalculation is
considered. Sample size was recalculated using conditional power arguments, where both
the assumed eﬀect from the planning phase and the mean of this eﬀect and the observed
eﬀect in the interim analysis was used. The timing of the interim analysis was deﬁned as
the ratio of the sample size in the ﬁrst stage and the sample size that would be required in
a corresponding study design for demonstrating eﬃcacy in the total population without
interim analysis. In simulation studies, diﬀerent interim timings were compared based
on the distribution of the overall sample size. In particular, the average sample size and
its standard deviation as well as the probability to achieve a sample size that is larger
than the sample size for the respective design without interim analysis was considered.
Results showed that diﬀerent selection rules, eﬀect sizes and prevalences have a smaller
impact, and an interim analysis after half the patients have been enrolled leads to the
smallest average sample size in many cases.
For both situations (ﬁxed and adapted sample size), the choice of the interim analysis
timing was investigated for a clinical trial example.
In summary, this thesis shows that the choice of the interim analysis timing in adaptive
enrichment designs has, in many cases, a substantial eﬀect on the power of the study or
the average sample size. However, the most appropriate timing depends on the eﬀect
sizes, the prevalence of the subgroup and the chosen selection rule, and should be selected
carefully in the planning phase for the speciﬁc scenario at hand.
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Deutsch
Diese Arbeit beschäftigt sich mit adaptiven Enrichment-Designs, die insbesondere in
der Entwicklung von zielgerichteten Therapien verwendet werden. Diese sind für die
Situation konzipiert, in der ein höherer Therapieeﬀekt in einer bestimmten Subgruppe
vermutet wird, gleichzeitig aber auch eine Wirksamkeit für die Gesamtpopulation nicht
ausgeschlossen werden kann. Die Idee dieses zweistuﬁgen Studiendesigns besteht darin,
basierend auf den beobachteten Eﬀekten in einer Interimanalyse zu entscheiden, ob die
Rekrutierung in der zweiten Stufe aus der Subgruppe oder der Gesamtpopulation er-
folgt und für welcher Population in der ﬁnalen Auswertung der Wirksamkeitsnachweis
durchgeführt werden soll.
In dieser Arbeit wurde der Einﬂuss des Interimzeitpunktes auf die Power einer Studie für
einen normalverteilten Endpunkt untersucht. Dabei wurden verschiedene Eﬀektgrößen
und Prävalenzen der Subgruppe sowie zwei verschiedene Entscheidungsregeln betrachtet.
Bei der ersten Entscheidungsregel wird die Diﬀerenz zwischen den Eﬀektschätzern aus
der Subgruppe und der Gesamtpopulation mit einem zuvor speziﬁzierten Schwellenwert
verglichen und entsprechend die Subgruppe oder die gesamte Patientenpopulation aus-
gewählt. Die zweite Entscheidungsregel, die betrachtet wurde, vergleicht die Eﬀekt-
schätzer aus der Subgruppe und der Gesamtpopulation mit jeweils einem Schwellenwert.
Bei dieser Entscheidungsregel können entweder nur die Subgruppe, nur die Gesamtpop-
ulation, beide Populationen, oder auch keine Population ausgewählt werden. Letztere
Option führt zu einem frühzeitigen Abbruch der Studie ohne Ablehnung einer Hypothese.
Im ersten Teil wurde der Einﬂuss des Interimzeitpunktes auf die Power der Studie für
eine feste Gesamtfallzahl untersucht. Die analytische Berechnung der Power war nicht
möglich, sodass die Power mit Hilfe von Simulationsstudien bestimmt wurde. Dabei
zeigte sich, dass die Power der Studie je nach Szenario unterschiedlich stark durch den
Interimzeitpunkt beeinﬂusst werden kann. Insbesondere führte die gewählte Entschei-
dungsregel zu verschiedenen Powercharakteristika in Abhängigkeit von der Zeit. Zum
Beispiel, ist die Power bei Verwendung der zweiten Entscheidungsregel, die auf den abso-
luten Eﬀektschätzern basiert, für frühe Interimanalysen eher gering, was durch die Op-
tion des frühzeitigen Abbruchs der Studie erklärt werden kann. Bei der ersten Entschei-
dungsregel, die auf der Diﬀerenz zwischen den Eﬀektschätzern basiert, gab es dagegen
einige Szenarien für die eine frühe Zwischenauswertung optimal bezüglich der Power war.
Zudem wurde das Powermaximum durch die Eﬀektgrößen und die Prävalenz der Sub-
gruppe beeinﬂusst. Dies macht deutlich, dass es nicht einen einzigen Interimzeitpunkt
gibt, der in jeder Situation optimal ist. Bei der Wahl des Zwischenauswertungszeit-
punktes sollten stattdessen die angenommenen Eﬀektgrößen und die Prävalenz sowie die
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gewählte Entscheidungsregel berücksichtigt werden.
Im zweiten Teil wurde ein adaptives Enrichment-Design mit Fallzahlrekalkulation be-
trachtet. Die Fallzahl wurde dabei mit Hilfe der conditional Power rekalkuliert, sowohl
basierend auf dem Eﬀekt aus der Planungsphase als auch basierend auf dem Mittel-
wert aus diesem Wert und dem beobachteten Eﬀekt in der Zwischenauswertung. Der
Zeitpunkt der Interimanalyse wurde hier als Verhältnis der Fallzahl in der ersten Stufe
und der Fallzahl, die man in einem entsprechenden Studiendesign für den Nachweis
eines Eﬀektes in der Gesamtpopulation ohne Interimanalyse benötigen würde, deﬁniert.
Verschiedene Interimzeitpunkte wurden anhand der Verteilung der Gesamtfallzahl ver-
glichen, die mit Hilfe von Simulationen bestimmt wurden. Insbesondere wurde die er-
wartete Fallzahl und deren Standardabweichung als auch die Wahrscheinlichkeit eine
Fallzahl zu erhalten, die größer ist als im entsprechenden Design ohne Interimanalyse,
untersucht. Hier zeigten verschiedene Entscheidungsregeln, Eﬀektgrößen und Prävalen-
zen einen weniger großen Einﬂuss, und eine Interimanalyse nach der Hälfte der Patienten,
die man im entsprechenden Design ohne Zwischenauswertung benötigt hätte, weist in
vielen Fällen eine geringe erwartete Fallzahl auf.
In beiden Teilen (feste Fallzahl und Fallzahlrekalkulation) wurde die Wahl des Inter-
imzeitpunktes auch für ein konkretes klinisches Beispiel untersucht.
Zusammengefasst zeigt die Arbeit, dass die Wahl des Interimzeitpunktes in adaptiven
Enrichment-Designs die Power der Studie oder die erwartete Fallzahl in vielen Fällen
wesentlich beeinﬂusst. Der optimale Zeitpunkt hängt dabei von den Eﬀektgrößen, der
Prävelenz der Subgruppe und der gewählten Entscheidungsregel ab, und sollte daher in
der Planungsphase in Abhängigkeit der vorliegenden Parameter mit Bedacht gewählt
werden.
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Appendix A
Derivation of Power Function
In the following, detailed derivation of the probability shown in formula (4.1.1) is pre-
sented referring to the rejection of H
(0)
0 :
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The probability for rejecting the hypothesis H
(+)
0 shown in formula (4.1.2) can be derived
in a similar way:
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t ASS± SD G+ sel. CP n > nfix
0.2 548± 573 0.916 0.78 0.038
0.35 676± 0 0.966 0 0
0.5 961± 0 0.986 0 0
0.65 1246± 0 0.994 0 0
0.8 1532± 0 0.997 0 0
(a) p = 0.2,∆− = 0,∆0 = 0.1, c = 0.2, nfix = 1902
t ASS± SD G+ sel. CP n > nfix
0.2 182± 130 0.5 0.9 0.306
0.35 177± 110 0.5 0.85 0.255
0.5 176± 91 0.501 0.79 0.205
0.65 180± 70 0.501 0.66 0.146
0.8 191± 43 0.5 0.27 0.069
(b) p = 0.2,∆− = 0.25,∆0 = 0.3, c = 0.2, nfix = 212
t ASS± SD G+ sel. CP n > nfix
0.2 89± 47 0.391 0.95 0.499
0.35 82± 42 0.357 0.89 0.422
0.5 78± 36 0.331 0.82 0.347
0.65 76± 28 0.309 0.7 0.256
0.8 79± 20 0.289 0.42 0.16
(c) p = 0.2,∆− = 0.5,∆0 = 0.5, c = 0.2, nfix = 77
Figure B.1: Distribution of sample size using the selection rule based on estimated
eﬀect diﬀerences with c = 0.2; p = 0.2. Sample size recalculation is based on the mean
of the eﬀect size from the planning phase and the interim eﬀect estimate.
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t ASS± SD G+ sel. CP n > nfix
0.2 144± 95 0.382 0.84 0.342
0.35 136± 83 0.345 0.78 0.287
0.5 131± 69 0.317 0.69 0.221
0.65 132± 50 0.294 0.48 0.138
0.8 140± 25 0.273 0.06 0.045
(a) p = 0.7,∆− = 0,∆0 = 0.35, c = 0.2, nfix = 156
t ASS± SD G+ sel. CP n > nfix
0.2 111± 65 0.268 0.85 0.42
0.35 103± 58 0.205 0.79 0.357
0.5 98± 49 0.163 0.7 0.277
0.65 97± 37 0.132 0.54 0.191
0.8 102± 24 0.107 0.19 0.096
(b) p = 0.7,∆− = 0.25,∆0 = 0.425, c = 0.2, nfix = 106
t ASS± SD G+ sel. CP n > nfix
0.2 84± 47 0.198 0.85 0.456
0.35 78± 42 0.131 0.78 0.378
0.5 73± 35 0.09 0.69 0.294
0.65 72± 26 0.063 0.5 0.187
0.8 76± 15 0.045 0.13 0.084
(c) p = 0.7,∆− = 0.5,∆0 = 0.5, c = 0.2, nfix = 77
Figure B.2: Distribution of sample size using the selection rule based on estimated
eﬀect diﬀerences with c = 0.2; p = 0.7. Sample size recalculation is based on the mean
of the eﬀect size from the planning phase and the interim eﬀect estimate.
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t ASS± SD corr. sel. CP n > nfix
0.2 686± 354 0.412 0.73 0
0.35 695± 21 0.457 0 0
0.5 981± 20 0.478 0 0
0.65 1266± 20 0.488 0 0
0.8 1552± 20 0.493 0 0
(a) p = 0.2,∆− = 0,∆0 = 0.1, c+ = 0.1, nfix = 1902
t ASS± SD corr. sel. CP n > nfix
0.2 235± 130 0.589 0.83 0.518
0.35 208± 101 0.661 0.65 0.403
0.5 195± 71 0.713 0.49 0.297
0.65 192± 35 0.751 0.26 0.155
0.8 211± 17 0.781 0 0.781
(b) p = 0.2,∆− = 0.25,∆0 = 0.3, c+ = 0.1, nfix = 212
t ASS± SD corr. sel. CP n > nfix
0.2 98± 49 0.557 0.75 0.598
0.35 93± 43 0.608 0.51 0.495
0.5 91± 36 0.643 0.3 0.695
0.65 87± 19 0.667 0 0.667
0.8 99± 19 0.686 0 0.686
(c) p = 0.2,∆− = 0.5,∆0 = 0.5, c+ = 0.1, nfix = 77
Figure B.3: Distribution of sample size using the selection rule based on absolute eﬀect
estimates with c+ = 0.3; p = 0.2. Sample size recalculation is based on the mean of the
eﬀect size from the planning phase and the interim eﬀect estimate.
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t ASS± SD corr. sel. CP n > nfix
0.2 150± 90 0.717 0.87 0.404
0.35 126± 68 0.793 0.68 0.243
0.5 144± 44 0.842 0.46 0.132
0.65 115± 4 0.877 0.04 0
0.8 138± 2 0.904 0 0
(a) p = 0.7,∆− = 0,∆0 = 0.35, c+ = 0.1, nfix = 156
t ASS± SD corr. sel. CP n > nfix
0.2 119± 65 0.69 0.9 0.538
0.35 98± 50 0.757 0.72 0.353
0.5 91± 38 0.802 0.56 0.225
0.65 90± 23 0.836 0.31 0.102
0.8 98± 2 0.861 0 0
(b) p = 0.7,∆− = 0.25,∆0 = 0.425, c+ = 0.1, nfix = 106
t ASS± SD corr. sel. CP n > nfix
0.2 91± 48 0.667 0.87 0.572
0.35 76± 37 0.726 0.68 0.414
0.5 70± 27 0.767 0.52 0.29
0.65 70± 17 0.798 0.31 0.154
0.8 75± 2 0.823 0 0
(c) p = 0.7,∆− = 0.5,∆0 = 0.5, c+ = 0.1, nfix = 77
Figure B.4: Distribution of sample size using the selection rule based on absolute eﬀect
estimates with c+ = 0.3; p = 0.7. Sample size recalculation is based on the mean of the
eﬀect size from the planning phase and the interim eﬀect estimate.
Appendix C
Selected R Program Code
C.1 Code for Design with Fixed Sample Size
l i b r a r y ( MASS )
l i b r a r y ( xlsx )
l i b r a r y ( matrixcalc )
l i b r a r y ( RColorBrewer )
l i b r a r y ( ggplot2 )
l i b r a r y ( tidyr )
##############################################################
# Function to c a l c u l a t e s e l e c t i o n and r e j e c t i o n p r o b a b i l i t i e s
# f o r s e l e c t i o n ru l e based on est imated e f f e c t d i f f e r e n c e s
##############################################################
##############################################################
# Parameters to s p e c i f y :
# p = preva l ence o f subgroup
# n = ov e r a l l sample s i z e per treatment group
# de l ta1 = standard i zed e f f e c t in subgroup
# de l ta2 = standard i zed e f f e c t in complement
# tv = vecto r o f in te r im ana l y s i s t imings
# m = number o f s imulated s t ud i e s
# c = thre sho ld o f s e l e c t i o n ru l e
# adj = method to con t r o l f o r mu l t i p l i c i t y , e i t h e r "ClosedTest ing " or
# "Bonfer ron i "
# alpha = s i g n i f i c a n c e l e v e l
# seed = seed value
##############################################################
##############################################################
# Returned va lue s ( v e c t o r s f o r d i f f e r e n t t )
# prSub = probab i l i t y to s e l e c t subgroup
# powerSub = probab i l i t y to r e j e c t nu l l hypothes i s o f subgroup
# powerTot = p r obab i l i t y to r e j e c t nu l l hypothes i s o f t o t a l populat ion
# powerOveral l = o v e r a l l power
##############################################################
Power_Sel1 <− f unc t i on (p , n , delta1 , delta2 , tv , m , c , adj , alpha , seed ) {
s e t . seed ( seed )
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delta0 <− p*delta1 + (1−p ) *delta2
prSub <− as . numeric ( )
powerSub <− as . numeric ( )
powerTot <− as . numeric ( )
powerOverall <− as . numeric ( )
i <− 0
f o r ( t in tv ) {
i <− i+1
n1 <− t *n # sample s i z e s tage I
n2 <− n − n1 # sample s i z e s tage I I
i f ( i s . positive . definite ( matrix ( c (2 /n1 , 2/n1 , 2/n1 , 2/ (n1*p ) ) , 2 , 2) ,
tol = 1e−8) ) {
# −−−−−−−−−−−−−−−−−−−−−−
# Stage I
# −−−−−−−−−−−−−−−−−−−−−−
Delta_1 <− mvrnorm (n=m , mu=c ( delta0 , delta1 ) , Sigma = matrix ( c (2 /n1 ,
2/n1 , 2/n1 , 2/ (n1*p ) ) , 2 , 2) )
# subgroup
Z1_1 <− Delta_1 [ , 2 ] * s q r t (n1*p/ 2)
p1_1 <− 1 − pnorm(Z1_1)
# t o t a l populat ion
Z0_1 <− Delta_1 [ , 1 ] * s q r t (n1/ 2)
p0_1 <− 1 − pnorm(Z0_1)
# combination o f p−va lue s ( Closed Test ing Procedure )
p01_1 <− apply ( rbind (2 * apply ( rbind (p1_1 , p0_1) , 2 , min ) ,
apply ( rbind (p1_1 , p0_1) , 2 , max) ) , 2 , min )
selSub <− i f e l s e ( Delta_1 [ , 1 ] + c < Delta_1 [ , 2 ] , 1 , 0)
# −−−−−−−−−−−−−−−−−−−−−−
# Stage I I
# −−−−−−−−−−−−−−−−−−−−−−
# i f subgroup i s s e l e c t e d
delta1_2 <− rnorm (n = m , mean = delta1 , sd = sq r t (2 /n2 ) )
Z1_2_sub <− delta1_2 * s q r t (n2/ 2)
U1_sub <− s q r t (p*n1/ (p*n1+n2 ) ) * Z1_1 + sq r t (n2/ (p*n1+n2 ) ) * Z1_2_
sub
p1_sub <− 1 − pnorm(U1_sub )
# combination o f p−va lue s ( Closed Test ing Procedure )
U01_sub <− s q r t (n1/n ) * qnorm(1−p01_1) + sq r t (n2/n ) * Z1_2_sub
p01_sub <− 1 − pnorm( U01_sub )
# i f t o t a l populat ion i s s e l e c t e d
APPENDIX C. SELECTED R PROGRAM CODE 95
i f ( i s . positive . definite ( matrix ( c (2 /n2 , 2/n2 , 2/n2 , 2/ (n2*p ) ) , 2 , 2 ) ,
tol=1e−8) ) {
Delta_2 <− mvrnorm (n = m , mu = c ( delta0 , delta1 ) , Sigma = matrix ( c
(2 /n2 , 2/n2 , 2/n2 , 2/ (n2*p ) ) , 2 , 2) )
Z0_2_tot <− Delta_2 [ , 1 ] * s q r t (n2/ 2)
U0_tot <− s q r t (n1/n ) * Z0_1 + sq r t (n2/n ) * Z0_2_tot
p0_tot <− 1 − pnorm(U0_tot )
# combination o f p−va lue s ( Closed Test ing Procedure )
U01_tot <− s q r t (n1/n ) * qnorm(1−p01_1) + sq r t (n2/n ) * Z0_2_tot
p01_tot <− 1 − pnorm( U01_tot )
}
}
p_s i n g l e <− i f e l s e ( selSub == 1 , p1_sub , p0_tot )
p_closed <− i f e l s e ( selSub == 1 , p01_sub , p01_tot )
prSub [ i ] <− sum( selSub )
i f ( adj == "Bonfe r ron i " ) {
powerSub [ i ] <− sum(p_s i n g l e [ selSub == 1 ] < alpha/ 4) /m
powerTot [ i ] <− sum(p_s i n g l e [ selSub == 0 ] < alpha/ 4) /m
}
i f ( adj == "ClosedTest ing " ) {
powerSub [ i ] <− sum(p_closed [ selSub == 1 ] < alpha/2 & p_s i n g l e [ selSub
== 1 ] < alpha/ 2) /m
powerTot [ i ] <− sum(p_closed [ selSub == 0 ] < alpha/2 & p_s i n g l e [ selSub
== 0 ] < alpha/ 2) /m
}
}
powerOverall <− powerSub + powerTot
re turn ( l i s t ( prSub = prSub , powerSub = powerSub , powerTot = powerTot ,
powerOverall = powerOverall , n = n ) )
}
##############################################################
# Function to c a l c u l a t e sample s i z e to a s sure a power o f 80%
# at a s p e c i f i c t iming t
##############################################################
##############################################################
# Parameters to s p e c i f y :
# p = preva l ence o f subgroup
# de l ta1 = standard i zed e f f e c t in subgroup
# de l ta2 = standard i zed e f f e c t in complement
# m = number o f s imulated s t ud i e s
# c = thre sho ld f o r s e l e c t i o n ru l e
# t = inte r im ana l y s i s t iming
# adj = method to con t r o l f o r mu l t i p l i c i t y , e i t h e r "ClosedTest ing " or
# "Bonfer ron i "
# alpha = s i g n i f i c a n c e l e v e l
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# seed = seed value
##############################################################
##############################################################
# Returned value :
# n = sample s i z e per group
##############################################################
calculate_n_Sel1 <− f unc t i on (p , delta1 , delta2 , m , c , t , adj , alpha , seed )
{
n_s t a r t <− 5
powerOverall <− 0
whi l e ( powerOverall < 0 . 8 ) {
n_s t a r t <− n_s t a r t + 50
res <− Power_Sel1 (p , n_sta r t , delta1 , delta2 , t , m , c , adj , alpha ,
seed )
powerOverall <− res$powerOverall
}
n_start2 <− n_s t a r t − 50
powerOverall <− 0
whi l e ( powerOverall < 0 . 8 ) {
n_start2 <− n_start2 + 1
res <− Power_Sel1 (p , n_start2 , delta1 , delta2 , t , m , c , adj , alpha ,
seed )
powerOverall <− res$powerOverall
}
n <− n_start2
re turn (n )
}
##############################################################
# Function to c a l c u l a t e s e l e c t i o n and r e j e c t i o n p r o b a b i l i t i e s
# f o r s e l e c t i o n ru l e based on abso lu t e e f f e c t e s t imate s
##############################################################
##############################################################
# Parameters to s p e c i f y :
# p = preva l ence o f subgroup
# n = ov e r a l l sample s i z e per treatment group
# de l ta1 = standard i zed e f f e c t in subgroup
# de l ta2 = standard i zed e f f e c t in complement
# tv = vecto r o f in te r im ana l y s i s t imings
# m = number o f s imulated s t ud i e s
# c1 , c0 = thre sho ld va lue s f o r s e l e c t i o n ru l e
# adj = method to con t r o l f o r mu l t i p l i c i t y , e i t h e r "ClosedTest ing " or
# "Bonfer ron i "
# alpha = s i g n i f i c a n c e l e v e l
# seed = seed value
##############################################################
##############################################################
# Returned va lue s ( v e c t o r s f o r d i f f e r e n t t ) :
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# prSub , prTot , prCop , prFut = p r obab i l i t y to s e l e c t subgroup ,
# t o t a l populat ion , co−primary ana ly s i s , f u t i l i t y stop
# powerSub = probab i l i t y to r e j e c t nu l l hypothes i s o f subgroup
# powerTot = p r obab i l i t y to r e j e c t nu l l hypothes i s o f t o t a l populat ion
# powerOveral l = o v e r a l l power
# powerBoth_cp = probab i l i t y to r e j e c t both hypotheses
# powerSub_cp = probab i l i t y to r e j e c t the nu l l hypothes i s o f subgroup and
# co−primary ana l y s i s i s s e l e c t e d
# powerTot_cp = probab i l i t y to r e j e c t the nu l l hypothes i s o f t o t a l pop .
# and co−primary ana l y s i s i s s e l e c t e d
# powerOveral l_cp = p robab i l i t y to r e j e c t at l e a s t one hypothes i s and
# co−primary ana l y s i s i s s e l e c t e d
# powerSub_Sub = probab i l i t y to r e j e c t the nu l l hypothes i s o f subgroup
# and subgroup only i s s e l e c t e d
# powerTot_Tot = p r obab i l i t y to r e j e c t the nu l l hypothes i s o f t o t a l pop .
# and t o t a l pop . i s s e l e c t e d
# n = sample s i z e
##############################################################
Power_Sel2 <− f unc t i on (p , n , delta1 , delta2 , tv , m , c1 , c0 , adj , alpha ,
seed ) {
s e t . seed ( seed )
z_alpha <− qnorm(1−alpha/ 2)
delta0 <− p*delta1 + (1−p ) *delta2
prSub <− as . numeric ( )
prTot <− as . numeric ( )
prCop <− as . numeric ( )
prFut <− as . numeric ( )
powerSub <− as . numeric ( )
powerTot <− as . numeric ( )
powerOverall <− as . numeric ( )
powerSub_cp <− as . numeric ( )
powerTot_cp <− as . numeric ( )
powerBoth_cp <− as . numeric ( )
powerOverall_cp <− as . numeric ( )
powerSub_Sub <− as . numeric ( )
powerTot_Tot <− as . numeric ( )
i <− 0
f o r ( t in tv ) {
i <− i + 1
n1 <− t * n # sample s i z e per group in s tage I
n2 <− n − n1 # sample s i z e per group in s tage I I
# −−−−−−−−−−−−−−−−−−−−−−
# Stage I
# −−−−−−−−−−−−−−−−−−−−−−
Delta_1 = mvrnorm (n=m , mu=c ( delta0 , delta1 ) , Sigma = matrix ( c (2 /n1 , 2/
n1 , 2/n1 , 2/ (n1*p ) ) , 2 , 2) )
# subgroup
Z1_1 = Delta_1 [ , 2 ] * s q r t (n1*p/ 2)
p1_1 = 1 − pnorm(Z1_1)
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# to t a l populat ion
Z0_1 = Delta_1 [ , 1 ] * s q r t (n1/ 2)
p0_1 = 1 − pnorm(Z0_1)
# combination o f p−va lue s ( Closed Test ing Procedure )
p01_1 = apply ( cbind (2 * apply ( cbind (p0_1 , p1_1) , 1 , min ) , apply ( cbind (
p0_1 , p1_1) , 1 , max) ) , 1 , min )
# −−−−−−−−−−−−−−−−−−−−−−
# Stage I I
# −−−−−−−−−−−−−−−−−−−−−−
# inte r im de c i s i o n :
selSub <− i f e l s e ( Delta_1 [ , 2 ] > c1 & Delta_1 [ , 1 ] <= c0 , 1 , 0)
selTot <− i f e l s e ( Delta_1 [ , 2 ] <= c1 & Delta_1 [ , 1 ] > c0 , 1 , 0)
selCop <− i f e l s e ( Delta_1 [ , 2 ] > c1 & Delta_1 [ , 1 ] > c0 , 1 , 0)
selFut <− i f e l s e ( Delta_1 [ , 2 ] <= c1 & Delta_1 [ , 1 ] <= c0 , 1 , 0)
# i f subgroup i s s e l e c t e d
delta1_2 <− rnorm (n = m , mean = delta1 , sd = sq r t (2 /n2 ) )
Z1_2 <− delta1_2 * s q r t (n2/ 2)
p1_2 <− 1 − pnorm(Z1_2)
U1 <− s q r t (p*n1/ (p*n1+n2 ) ) *qnorm(1−p1_1) + sq r t (n2/ (n1*p+n2 ) ) *qnorm(1−
p1_2)
U01 <− s q r t (n1/n ) * qnorm(1−p01_1) + sq r t (n2/n ) * qnorm(1−p1_2) #
c l o s ed t e s t i n g
i f ( adj == "ClosedTest ing " ) {
sigSub <− U01 > z_alpha & U1 > z_alpha
}
i f ( adj == "Bonfe r ron i " ) {
sigSub <− 1 − pnorm(U1 ) < alpha/4
}
# i f t o t a l populat ion i s s e l e c t e d
Delta_2 <− mvrnorm (n = m , mu = c ( delta0 , delta1 ) , Sigma = matrix ( c (2 /
n2 , 2/n2 , 2/n2 , 2/ (n2*p ) ) , 2 , 2) )
Z0_2 <− Delta_2 [ , 1 ] * s q r t (n2/ 2)
p0_2 <− 1 − pnorm(Z0_2)
U0 <− s q r t (n1/n ) * Z0_1 + sqr t (n2/n ) * Z0_2
U01 <− s q r t (n1/n ) * qnorm(1−p01_1) + sq r t (n2/n ) * Z0_2
i f ( adj == "ClosedTest ing " ) {
sigTot <− U01 > z_alpha & U0 > z_alpha
}
i f ( adj == "Bonfe r ron i " ) {
sigTot <− 1 − pnorm(U0 ) < alpha/4
}
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# i f co−primary ana l y s i s i s s e l e c t e d
# subgroup
Z1_2 <− Delta_2 [ , 2 ] * s q r t (n2*p/ 2)
p1_2 <− 1 − pnorm(Z1_2)
# combination o f p−va lue s ( Closed Test ing Procedure )
p01_2 <− apply ( cbind (2 * apply ( cbind (p0_2 , p1_2) , 1 , min ) , apply ( cbind
(p0_2 , p1_2) , 1 , max) ) , 1 , min )
U0 <− s q r t (n1/n ) * Z0_1 + sqr t (n2/n ) * Z0_2
U1 <− s q r t (n1/n ) * Z1_1 + sqr t (n2/n ) * Z1_2
U01 <− s q r t (n1/n ) * qnorm(1−p01_1) + sq r t (n2/n ) * qnorm(1−p01_2)
i f ( adj == "ClosedTest ing " ) {
sigTot_cp <− U01 > z_alpha & U0 > z_alpha
sigSub_cp <− U01 > z_alpha & U1 > z_alpha
}
i f ( adj == "Bonfe r ron i " ) {
sigTot_cp <− 1 − pnorm(U0 ) < alpha/4
sigSub_cp <− 1 − pnorm(U1 ) < alpha/4
}
# Se l e c t i o n P r o b a b i l i t i e s
prSub [ i ] <− sum( selSub , na . rm = TRUE ) / m
prTot [ i ] <− sum( selTot , na . rm = TRUE ) / m
prCop [ i ] <− sum( selCop , na . rm = TRUE ) / m
prFut [ i ] <− sum( selFut , na . rm =TRUE ) / m
# Power
# uncond i t i ona l l y
powerSub [ i ] <− sum( sigSub * selSub | sigSub_cp * selCop , na . rm = TRUE )
/ m
powerTot [ i ] <− sum( sigTot * selTot | sigTot_cp * selCop , na . rm=TRUE ) /
m
powerOverall [ i ] <− sum( sigTot * selTot | sigSub * selSub | sigSub_cp *
selCop |
sigTot_cp * selCop , na . rm = TRUE ) / m
# i f co−primary ana l y s i s i s s e l e c t e d
powerBoth_cp [ i ] = sum( selCop * sigSub_cp * sigTot_cp , na . rm = TRUE ) /
m
powerSub_cp [ i ] = sum( selCop * sigSub_cp , na . rm = TRUE ) / m
powerTot_cp [ i ] = sum( selCop * sigTot_cp , na . rm = TRUE ) / m
powerOverall_cp [ i ] = sum( selCop * ( sigTot_cp | sigSub_cp ) , na . rm =
TRUE ) / m
# i f subgroup only i s s e l e c t e d
powerSub_Sub [ i ] = sum( sigSub * selSub , na . rm = TRUE ) / m
# i f t o t a l populat ion i s s e l e c t e d
powerTot_Tot [ i ] = sum( sigTot * selTot , na . rm=TRUE ) / m
}
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re turn ( l i s t ( prSub = prSub , prTot = prTot , prCop = prCop , prFut = prFut ,
powerSub = powerSub , powerTot = powerTot , powerOverall =
powerOverall ,
powerBoth_cp = powerBoth_cp , powerSub_cp = powerSub_cp ,
powerTot_cp = powerTot_cp , powerOverall_cp = powerOverall
_cp ,
powerSub_Sub = powerSub_Sub , powerTot_Tot = powerTot_Tot , n
= n ) )
}
##############################################################
# Function to c a l c u l a t e sample s i z e to a s sure a s p e c i f i c power
# at a s p e c i f i c t iming t
##############################################################
##############################################################
# Parameters to s p e c i f y :
# p = preva l ence o f subgroup
# de l ta1 = standard i zed e f f e c t in subgroup
# de l ta2 = standard i zed e f f e c t in complement
# m = number o f s imulated s t ud i e s
# c1 , c0 = thre sho ld va lue s f o r s e l e c t i o n ru l e
# t = inte r im ana l y s i s t iming
# adj = method to con t r o l f o r mu l t i p l i c i t y , e i t h e r "ClosedTest ing " or
# "Bonfer ron i "
# alpha = s i g n i f i c a n c e l e v e l
# seed = seed value
##############################################################
##############################################################
# Returned value :
# n = sample s i z e per group
##############################################################
calculate_n_Sel2 <− f unc t i on (p , delta1 , delta2 , m , c1 , c0 , t , adj , alpha ,
seed ) {
s e t . seed ( seed )
n_s t a r t <− 0
powerOverall <− 0
whi l e ( powerOverall < 0 . 8 ) {
n_s t a r t <− n_s t a r t + 50
res <− Power_Sel2 (p , n_sta r t , delta1 , delta2 , t , m , c1 , c0 , adj , alpha
, seed )
powerOverall <− res$powerOverall
}
n_start2 <− n_s t a r t − 50
powerOverall <− 0
whi l e ( powerOverall < 0 . 8 ) {
n_start2 <− n_start2 + 1
res <− Power_Sel2 (p , n_start2 , delta1 , delta2 , t , m , c1 , c0 , adj ,
alpha , seed )
powerOverall <− res$powerOverall
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}
n <− n_start2
re turn (n )
}
##############################################################
# Function to p l o t graph ic showing power f o r d i f f e r e n t in te r im ana l y s i s
# t imings and e f f e c t s i z e s in the complementary group
##############################################################
##############################################################
# Parameters to s p e c i f y :
# p = preva l ence o f subgroup
# de l ta1 = standard i zed e f f e c t in subgroup
# de l ta2v = vecto r o f s tandard ized e f f e c t s in complement
# tv = vecto r o f in te r im ana l y s i s t imings
# m = number o f s imulated s t ud i e s
# c = thre sho ld o f s e l e c t i o n ru l e ( vec to r ( c1 , c0 ) i f s e l_ru l e = 2)
# adj = method to con t r o l f o r mu l t i p l i c i t y , e i t h e r "ClosedTest ing " or
# "Bonfer ron i "
# alpha = s i g n i f i c a n c e l e v e l
# seed = seed value
# s e l_ru l e = 1 f o r s e l e c t i o n ru l e based on est imated e f f e c t d i f f e r e n c e s ,
# = 2 f o r s e l e c t i o n ru l e based on abso lu t e e f f e c t e s t imate s
##############################################################
Plot_Power <− f unc t i on (p , delta1 , delta2v , tv , m , c , adj , alpha , seed , sel
_rule ) {
power_m <− matrix ( rep (NA , l ength (tv ) * l ength ( delta2v ) ) , l ength ( delta2v )
, l ength (tv ) )
d i f f_03_07 <− rep (NA , l ength ( delta2v ) )
ma_vec <− rep (NA , l ength ( delta2v ) )
mi_vec <− rep (NA , l ength ( delta2v ) )
s <− 0
f o r ( delta2 in delta2v ) {
s <− s+1
delta0 <− p*delta1 + (1−p ) *delta2
i f ( sel_rule == 1) {
n <− calculate_n_Sel1 (p , delta1 , delta2 , m , c , t , adj , alpha , seed )
res <− Power_Sel1 (p , n , delta1 , delta2 , tv , m , c , adj , alpha , seed )
}
i f ( sel_rule == 2) {
n <− calculate_n_Sel2 (p , delta1 , delta2 , m , c [ 1 ] , c [ 2 ] , t , adj ,
alpha , seed )
res <− Power_Sel2 (p , n , delta1 , delta2 , tv , m , c [ 1 ] , c [ 2 ] , adj ,
alpha , seed )
}
i30 <− which (tv == 0 . 3 )
i70 <− which (tv == 0 . 7 )
t30_70 <− tv [ i30 : i70 ]
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mi <− min( res$powerOverall [ i30 : i70 ] )
ma <− max( res$powerOverall [ i30 : i70 ] )
mi_vec [ s ] <− min( res$powerOverall [ i30 : i70 ] ) −0.8
ma_vec [ s ] <− max( res$powerOverall [ i30 : i70 ] ) −0.8
t_mi <− t30_70 [ which ( res$powerOverall [ i30 : i70 ] == min ( res$powerOverall
[ i30 : i70 ] ) ) ]
t_ma <− t30_70 [ which ( res$powerOverall [ i30 : i70 ] == max( res$powerOverall
[ i30 : i70 ] ) ) ]
d i f f_03_07 [ s ] <− round (ma−mi , 4 )
power_m [ s , ] <− res$powerOverall
}
co l <− c ( " red4 " , " red3 " , " red " , rgb ( 1 , 0 . 4 , 0 , 1 ) , rgb ( 1 , 0 . 6 , 0 ,1) , rgb
( 1 , 0 . 8 , 0 ,1) ,
rgb (1 , 0 . 9 , 0 ,1) , rgb ( 1 , 1 , 0 , 0 . 4 ) , rgb ( 1 , 1 , 0 , 0 . 1 ) )
power_co l_1 <− i f e l s e ( power_m < 0.73 , c o l [ 9 ] , 0)
power_co l_2 <− i f e l s e ( power_m < 0.75 & power_m >= 0.73 , c o l [ 8 ] , power_
co l_1)
power_co l_3 <− i f e l s e ( power_m < 0.77 & power_m >= 0.75 , c o l [ 7 ] , power_
co l_2)
power_co l_4 <− i f e l s e ( power_m < 0.79 & power_m >= 0.77 , c o l [ 6 ] , power_
co l_3)
power_co l_5 <− i f e l s e ( power_m < 0.81 & power_m >= 0.79 , c o l [ 5 ] , power_
co l_4)
power_co l_6 <− i f e l s e ( power_m < 0.83 & power_m >= 0.81 , c o l [ 4 ] , power_
co l_5)
power_co l_7 <− i f e l s e ( power_m < 0.85 & power_m >= 0.83 , c o l [ 3 ] , power_
co l_6)
power_co l_8 <− i f e l s e ( power_m < 0.87 & power_m >= 0.85 , c o l [ 2 ] , power_
co l_7)
power_co l_9 <− i f e l s e ( power_m >= 0.87 , c o l [ 1 ] , power_co l_8)
op <− par ( mar = c (5 , 6 , 0 , 2 ) + 0 . 1 )
p l o t ( 0 . 5 , 1 , xlim = c ( 0 , 1 . 3 ) , ylim = c ( 0 . 3 , l ength ( delta2v ) +1.6) ,
xlab = " t              " , ylab = "" , yaxt = "n" , xaxt = "n" , las =
1 ,
cex . lab = 2 , cex . main = 2)
t i t l e ( ylab = bquote ( Delta [ "−" ] ) , cex . lab = 2 , line = 4 . 5 )
ax i s (2 , at = 1 : l ength ( delta2v ) , l a b e l s = delta2v , las = 1 , cex . a x i s =
1 . 5 )
ax i s (1 , at = c (0 , 0 . 2 , 0 . 4 , 0 . 6 , 0 . 8 , 1) , l a b e l s = c ( " 0 .0 " , " 0 . 2 " , " 0 . 4 "
, " 0 . 6 " , " 0 . 8 " , " 1 .0 " ) , las = 1 , cex . a x i s = 1 . 5 )
f o r (j in 1 : l ength ( delta2v ) ) {
f o r (i in 1 : l ength (tv ) ) {
l i n e s ( c (tv [ i ] − 0 .0125 , tv [ i ] + 0 .0125) , c (j , j ) , c o l = power_co l_9 [ j
, i ] ,
lwd = 20 , lend = "butt " )
}
}
text ( rep ( 1 . 2 , l ength ( delta2v ) ) , 1 : l ength ( delta2v ) , paste ( format ( round (
d i f f_03_07* 100 ,1) , nsmall = 1) , "%" ) , pos = 2 , cex = 1 . 5 )
t ex t ( 0 . 9 5 , l ength ( delta2v ) + 1 . 6 , "power range " , pos = 4 , cex = 1 . 4 )
t ex t ( 0 . 9 5 , l ength ( delta2v ) + 0 . 8 , exp r e s s i on ( paste ( " f o r  " , t %in% " [ 0 . 3 ,
 0 . 7 ] " ) ) , pos = 4 , cex = 1 . 4 )
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}
##############################################################
# Function to p l o t graph ic showing s e l e c t i o n and r e j e c t i o n p r o b a b i l i t i e s
# f o r d i f f e r e n t in te r im ana l y s i s t imings
##############################################################
##############################################################
# Parameters to s p e c i f y :
# p = preva l ence o f subgroup
# de l ta1 = standard i zed e f f e c t in subgroup
# de l ta2v = vecto r o f s tandard ized e f f e c t s in complement
# tv = vecto r o f in te r im ana l y s i s t imings
# m = number o f s imulated s t ud i e s
# c = thre sho ld o f s e l e c t i o n ru l e ( vec to r ( c1 , c0 ) i f s e l_ru l e = 2)
# adj = method to con t r o l f o r mu l t i p l i c i t y , e i t h e r "ClosedTest ing " or
# "Bonfer ron i "
# alpha = s i g n i f i c a n c e l e v e l
# seed = seed value
# s e l_ru l e = 1 f o r s e l e c t i o n ru l e based on est imated e f f e c t d i f f e r e n c e s ,
# = 2 f o r s e l e c t i o n ru l e based on abso lu t e e f f e c t e s t imate s
##############################################################
Plot_SelProb <− f unc t i on (pv , delta1 , delta2v , tv , m , c , adj , alpha , seed ,
sel_rule ) {
p_long <− as . numeric ( )
delta2_long <− as . numeric ( )
tv_long <− as . numeric ( )
prSub <− as . numeric ( )
prTot <− as . numeric ( )
prCop <− as . numeric ( )
prFut <− as . numeric ( )
powerSub <− as . numeric ( )
powerTot <− as . numeric ( )
powerOverall <− as . numeric ( )
powerSub_Sub <− as . numeric ( )
powerTot_Tot <− as . numeric ( )
powerOverall <− as . numeric ( )
powerOverall_cp <− as . numeric ( )
i f ( sel_rule == 1) {
f o r (p in pv ) {
f o r ( delta2 in delta2v ) {
p_long <− c (p_long , rep (p , l ength (tv ) ) )
delta2_long <− c ( delta2_long , rep ( delta2 , l ength (tv ) ) )
tv_long <− c (tv_long , tv )
n <− calculate_n_Sel1 (p , delta1 , delta2 , m , c , 0 . 5 , adj , alpha ,
seed )
res <− Power_Sel1 (p , n , delta1 , delta2 , tv , m , c , adj , alpha , seed
)
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prSub <− c ( prSub , res$prSub )
powerSub <− c ( powerSub , res$powerSub )
powerTot <− c ( powerTot , res$powerTot )
powerOverall <− c ( powerOverall , res$powerOverall )
}
}
res_tab <− data . frame ( prSub = prSub/m , prTot = 1 − prSub/m , powerSub =
powerSub , powerTot = powerTot ,
powerOverall = powerOverall , p_long = p_long ,
delta2_long = delta2_long , tv_long = tv_long )
res_long <− gather ( res_tab , var , prob , prSub : powerOverall , f a c t o r_key
= TRUE )
coltyp <− brewer . pal (5 , " Set1 " )
coltyp <− coltyp [ c (1 , 2 , 1 , 2 , 3) ]
ltyp <− c (2 , 2 , 1 , 1 , 1)
}
i f ( sel_rule == 2) {
f o r (p in pv ) {
f o r ( delta2 in delta2v ) {
p_long <− c (p_long , rep (p , l ength (tv ) ) )
delta2_long <− c ( delta2_long , rep ( delta2 , l ength (tv ) ) )
tv_long <− c (tv_long , tv )
n <− calculate_n_Sel2 (p , delta1 , delta2 , m , c [ 1 ] , c [ 2 ] , 0 . 5 , adj ,
alpha , seed )
res <− Power_Sel2 (p , n , delta1 , delta2 , tv , m , c [ 1 ] , c [ 2 ] , adj ,
alpha , seed )
prSub <− c ( prSub , res$prSub )
prTot <− c ( prTot , res$prTot )
prCop <− c ( prCop , res$prCop )
prFut <− c ( prFut , res$prFut )
powerSub_Sub <− c ( powerSub_Sub , res$powerSub_Sub )
powerTot_Tot <− c ( powerTot_Tot , res$powerTot_Tot )
powerOverall_cp <− c ( powerOverall_cp , res$powerOverall_cp )
powerOverall <− c ( powerOverall , res$powerOverall )
}
}
res_tab <− data . frame ( prSub = prSub , prTot = prTot , prCop = prCop ,
prFut = prFut ,
powerSub_Sub = powerSub_Sub , powerTot_Tot = powerTot_Tot ,
powerOverall_cp = powerOverall_cp , powerOverall = powerOverall ,
p_long = p_long , delta2_long = delta2_long , tv_long = tv_long )
res_long <− gather ( res_tab , var , prob , prSub : powerOverall , f a c t o r_key
= TRUE )
coltyp <− brewer . pal (5 , " Set1 " )
coltyp <− coltyp [ c (1 , 2 , 4 , 5 , 1 , 2 , 4 , 3) ]
ltyp <− c (2 , 2 , 2 , 2 , 1 , 1 , 1 , 1)
}
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p . labs <− paste ( "p = " , pv , sep = "" )
names (p . labs ) <− pv
delta2 . labs <− as . cha rac t e r ( )
f o r (i in 1 : l ength ( delta2v ) ) {
delta2 . labs <− c ( delta2 . labs , bquote ( Delta [ "−" ] *plain ( " = " ) * . ( delta2v
[ i ] ) ) )
}
names ( delta2 . labs ) <− delta2v
res_long %>%
ggplot ( aes (x = tv_long , y = prob , colour = var , linetype = var , group
= var ) ) +
geom_line ( size=0.6) +
facet_gr id (p_long ~ delta2_long , labeller = label_bquote ( cols = Delta [
"−" ] ~ "=" ~ . ( delta2_long ) , rows = p~"="~ . ( p_long ) ) ) +
s c a l e_linetype_manual ( values = ltyp ) +
s c a l e_colour_manual ( values = coltyp ) +
xlab ( " t " ) +
ylab ( " Probab i l i t y " ) +
ylim ( c (0 , 1) ) +
theme_bw ( ) +
theme ( l egend . position = "none" , ax i s . t ex t = element_text ( size = 11) ,
ax i s . t i t l e = element_text ( size = 13) ,
strip . t ex t . x = element_text ( size = 11) , strip . t ex t . y = element_
text ( size = 11) )
}
C.2 Code for Design with Sample Size Reassessment
l i b r a r y ( MASS )
l i b r a r y ( ggplot2 )
l i b r a r y ( RColorBrewer )
##############################################################
# Function to c a l c u l a t e sample s i z e d i s t r i b u t i o n
# f o r s e l e c t i o n ru l e based on est imated e f f e c t d i f f e r e n c e s
##############################################################
##############################################################
# Parameters to s p e c i f y :
# p = preva l ence o f subgroup
# t = inte r im ana l y s i s t iming
# de l ta1 = standard i zed e f f e c t in subgroup
# de l ta2 = standard i zed e f f e c t in complement
# m = number o f s imulated s t ud i e s
# c = thre sho ld f o r s e l e c t i o n ru l e
# beta = type I I e r r o r ra t e
# alpha = s i g n i f i c a n c e l e v e l
# CP = cond i t i o na l power f o r e f f e c t s i z e from planning phase (="pp")
# or mean between e f f e c t s i z e from planning phase and observed e f f e c t
# from inte r im ana l y s i s (="ppia ")
# adj = method to con t r o l f o r mu l t i p l i c i t y , e i t h e r "ClosedTest ing "
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# or "Bonfer ron i "
# seed = seed value
# H0 = TRUE i f e f f e c t s in both popu la t i ons are 0 ( de l t a1 and de l t a2 have
# to be s p e c i f i e d then as the assumed e f f e c t s in the planning phase
# to c a l c u l a t e n_f i x
##############################################################
##############################################################
# Returned va lue s :
# 1 . data frame : f o r each s imulated study :
## se lSub = 1 i f subgroup i s s e l e c t ed , 0 otherwi se
## s i g_a l l = 1 i f s i g n i f i c a n t r e su l t , 0 o therwi se
## n2 = sample s i z e in second s tage
## n = ov e r a l l sample s i z e
# 2 . data frame : input parameters p lus
# n_f i x = sample s i z e in f i x ed des ign
# conP = adjusted c ond i t i o na l power to reach an o v e r a l l power o f 80%
# s e l_ru l e = 1 ( s e l e c t i o n ru l e )
##############################################################
Samplesize_Sel1 <− f unc t i on (p , t , delta1 , delta2 , m , c , beta , alpha , CP ,
adj , seed , H0 = FALSE ) {
s e t . seed ( seed )
delta0 <− p*delta1 + (1−p ) *delta2
n_f i x <− c e i l i n g (2 * ( qnorm(1−alpha/ 4) + qnorm(1−beta ) )^2 / delta0^2) #
sample s i z e per group in a f i x ed des ign
i f (H0 == TRUE ) {
delta1 <− 0
delta2 <− 0
delta0 <− 0
}
n1 <− t *n_f i x # sample s i z e s tage I
# −−−−−−−−−−−−−−−−−−−−−−
# Stage I
# −−−−−−−−−−−−−−−−−−−−−−
Delta_1 <− mvrnorm (n = m , mu = c ( delta0 , delta1 ) , Sigma = matrix ( c (2 /n1 ,
2/n1 , 2/n1 , 2/ (n1*p ) ) , 2 , 2 ) )
# subgroup
Z1_1 <− Delta_1 [ , 2 ] * s q r t (n1*p/ 2)
p1_1 <− 1 − pnorm(Z1_1)
# t o t a l populat ion
Z0_1 <− Delta_1 [ , 1 ] * s q r t (n1/ 2)
p0_1 <− 1 − pnorm(Z0_1)
# combination o f p−va lue s ( Closed Test ing Procedure )
p01_1 <− apply ( rbind (2 * apply ( rbind (p1_1 , p0_1) , 2 , min ) ,
apply ( rbind (p1_1 , p0_1) , 2 , max) ) , 2 , min )
selSub <− i f e l s e ( Delta_1 [ , 1 ] + c < Delta_1 [ , 2 ] , 1 , 0)
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# −−−−−−−−−−−−−−−−−−−−−−
# Stage I I
# −−−−−−−−−−−−−−−−−−−−−−
i f (CP == "pp" ) { # cond i t i o na l power us ing the e f f e c t s i z e from the
planning s tage
mu0 <− rep ( delta0 , m )
mu1 <− rep ( delta1 , m )
}
i f (CP == "ppia " ) { # cond i t i o na l power us ing the mean o f the e f f e c t s i z e
from the planning s tage and the observed inte r im e f f e c t
mu0 <− ( rep ( delta0 , m ) + Delta_1 [ , 1 ] ) / 2
mu1 <− ( rep ( delta1 , m ) + Delta_1 [ , 2 ] ) / 2
}
poweri <− 0
beta_CP_v <− ( 1 00 : 1 ) /100
i f (H0 == TRUE ) {
beta_CP_v <− beta
}
f o r ( beta_CP in beta_CP_v ) {
# i f subgroup i s s e l e c t e d
# sample s i z e f o r s tage I I
br <− (qnorm(1−alpha/ 4) / sq r t (1− t ) − qnorm( beta_CP ) − s q r t ( t /(1− t ) ) *
Z1_1)
br <− i f e l s e (br < 0 , 0 , br )
fz <− cbind (br^2 * 2 / mu1^2 , 2*n_f i x − n1 )
n2_sub <− apply (fz , 1 , min )
n2_sub <− i f e l s e (n2_sub < 10 , 10 , n2_sub )
# t e s t s in s tage I I
delta1_2 <− rnorm (n = m , mean = delta1 , sd = sq r t (2 /n2_sub ) )
Z1_2_sub <− delta1_2 * s q r t (n2_sub/2)
U1_sub <− s q r t ( t ) *Z1_1 + sq r t (1− t ) *Z1_2_sub
# combination o f p−va lue s ( Closed Test ing Procedure )
U01_sub <− s q r t ( t ) * qnorm(1−p01_1) + sq r t (1− t ) *Z1_2_sub
p01_sub <− 1 − pnorm( U01_sub )
i f ( adj == "ClosedTest ing " ) {
sig_sub <− i f e l s e ( p01_sub < alpha/2 & 1 − pnorm(U1_sub ) < alpha/ 2 ,
1 , 0)
}
i f ( adj == "Bonfe r ron i " ) {
sig_sub <− i f e l s e (1 − pnorm(U1_sub ) < alpha/ 4 , 1 , 0)
}
# i f t o t a l populat ion i s s e l e c t e d
# sample s i z e f o r s tage I I
br <− (qnorm(1−alpha/ 4) / sq r t (1− t ) − qnorm( beta_CP ) − s q r t ( t /(1− t ) ) *
Z0_1)
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br <− i f e l s e (br < 0 , 0 , br )
fz <− cbind (br^2 * 2 / mu0^2 , 2*n_f i x − n1 )
n2_tot <− apply (fz , 1 , min )
n2_tot <− i f e l s e (n2_tot < 10 , 10 , n2_tot )
# t e s t s in s tage I I
delta0_2 <− rnorm (n = m , mean = delta0 , sd = sq r t (2 /n2_tot ) )
Z0_2_tot <− delta0_2 * s q r t (n2_tot/ 2)
U0_tot <− s q r t ( t ) *Z0_1 + sq r t (1− t ) *Z0_2_tot
# combination o f p−va lue s ( Closed Test ing Procedure )
U01_tot <− s q r t ( t ) *qnorm(1−p01_1) + sq r t (1− t ) *Z0_2_tot
p01_tot <− 1 − pnorm( U01_tot )
i f ( adj == "ClosedTest ing " ) {
sig_tot = i f e l s e ( p01_tot < alpha/2 & 1 − pnorm(U0_tot ) < alpha/ 2 , 1 ,
0)
}
i f ( adj == "Bonfe r ron i " ) {
sig_tot = i f e l s e (1 − pnorm(U0_tot ) < alpha/ 4 , 1 , 0)
}
# sample s i z e
n2_v <− round ( i f e l s e ( selSub == 1 , n2_sub , n2_tot ) )
n_v <− round (n1 + n2_v )
# power
sig_a l l <− i f e l s e ( selSub == 1 , sig_sub , sig_tot )
poweri <− mean( sig_a l l )
i f ( poweri >= 0 . 8 ) break
}
return ( l i s t ( data . frame ( selSub = selSub , sig_a l l = sig_a l l , n2 = n2_v , n
= n_v ) ,
data . frame (p = p , t = t , delta1 = delta1 , delta2 = delta2 , m = m , c =
c ,
beta = beta , alpha = alpha , CP = CP , n_f i x = n_f ix , conP = 1−beta_CP ,
sel_rule = 1) ) )
}
##############################################################
# Function to c a l c u l a t e sample s i z e d i s t r i b u t i o n
# f o r s e l e c t i o n ru l e based on abso lu t e e f f e c t e s t imate s
##############################################################
##############################################################
# Parameters to s p e c i f y :
# p = preva l ence o f subgroup
# t = inte r im ana l y s i s t iming
# de l ta1 = standard i zed e f f e c t in subgroup
# de l ta2 = standard i zed e f f e c t in complement
# m = number o f s imulated s t ud i e s
# c = thre sho ld f o r s e l e c t i o n ru l e
# beta = type I I e r r o r to c a l c u l a t e sample s i z e o f f i x ed des ign
# alpha = s i g n i f i c a n c e l e v e l
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# CP = cond i t i o na l power f o r e f f e c t s i z e from planning phase (="pp")
# or mean between e f f e c t s i z e from planning phase and observed
# e f f e c t from inte r im ana l y s i s (="ppia ")
# adj = method to con t r o l f o r mu l t i p l i c i t y , e i t h e r "ClosedTest ing "
# or "Bonfer ron i "
# seed = seed value
# H0 = TRUE i f e f f e c t s in both popu la t i ons are 0 ( de l t a1 and de l t a2 have
# to be s p e c i f i e d then as the assumed e f f e c t s in the planning phase
# to c a l c u l a t e n_f i x
##############################################################
##############################################################
# Returned va lue s :
# 1 . data frame : f o r each s imulated study :
## se lSub = 1 i f subgroup i s s e l e c t ed , 0 otherwi se
## s i g_a l l = 1 i f s i g n i f i c a n t r e su l t , 0 o therwi se
## n2 = sample s i z e in second s tage
## n = ov e r a l l sample s i z e
# 2 . data frame : input parameters p lus
# n_f i x = sample s i z e in f i x ed des ign
# conP = adjusted c ond i t i o na l power to reach an o v e r a l l power o f 80%
# s e l_ru l e = 2 ( s e l e c t i o n ru l e )
##############################################################
Samplesize_Sel2 <− f unc t i on (p , t , delta1 , delta2 , m , c0 , c1 , beta , alpha ,
CP , adj , seed , H0 = FALSE ) {
s e t . seed ( seed )
delta0 <− p*delta1 + (1−p ) *delta2
n_f i x <− c e i l i n g (2 * (qnorm(1−alpha/ 4) + qnorm(1−beta ) )^2 / delta0^2)
i f (H0 == TRUE ) {
delta1 <− 0
delta2 <− 0
delta0 <− 0
}
n1 <− t * n_f i x
# −−−−−−−−−−−−−−−−−−−−−−
# Stage I
# −−−−−−−−−−−−−−−−−−−−−−
Delta_1 <− mvrnorm (n = m , mu = c ( delta0 , delta1 ) , Sigma = matrix ( c (2 /n1 ,
2/n1 , 2/n1 , 2/ (n1*p ) ) , 2 , 2) )
# subgroup
Z1_1 <− Delta_1 [ , 2 ] * s q r t (n1*p/ 2)
p1_1 <− 1 − pnorm(Z1_1)
# t o t a l populat ion
Z0_1 <− Delta_1 [ , 1 ] * s q r t (n1/ 2)
p0_1 <− 1 − pnorm(Z0_1)
# combination o f p−va lue s ( Closed Test ing Procedure )
p01_1 <− apply ( rbind (2 *apply ( rbind (p1_1 , p0_1) , 2 , min ) ,
apply ( rbind (p1_1 , p0_1) , 2 , max) ) , 2 , min )
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# −−−−−−−−−−−−−−−−−−−−−−
# Stage I I
# −−−−−−−−−−−−−−−−−−−−−−
# inte r im de c i s i o n :
selSub <− i f e l s e ( Delta_1 [ , 2 ] > c1 & Delta_1 [ , 1 ] <= c0 , 1 , 0)
selTot <− i f e l s e ( Delta_1 [ , 2 ] <= c1 & Delta_1 [ , 1 ] > c0 , 1 , 0)
selCop <− i f e l s e ( Delta_1 [ , 2 ] > c1 & Delta_1 [ , 1 ] > c0 , 1 , 0)
selFut <− i f e l s e ( Delta_1 [ , 2 ] <= c1 & Delta_1 [ , 1 ] <= c0 , 1 , 0)
i f (CP == "pp" ) {
mu0 <− rep ( delta0 , m )
mu1 <− rep ( delta1 , m )
}
i f (CP == "ppia " ) {
mu0 <− ( rep ( delta0 , m ) + Delta_1 [ , 1 ] ) /2
mu1 <− ( rep ( delta1 , m ) + Delta_1 [ , 2 ] ) /2
}
poweri = 0
beta_CP_v = (100 : 1 ) /100
i f (H0 == TRUE ) {
beta_CP_v <− beta
}
f o r ( beta_CP in beta_CP_v ) {
# i f subgroup i s s e l e c t e d
# sample s i z e f o r s tage I I
br <− (qnorm(1−alpha/ 4) / sq r t (1− t ) − qnorm( beta_CP ) − s q r t ( t /(1− t ) ) *
Z1_1)
br <− i f e l s e (br < 0 , 0 , br )
fz <− cbind (br^2 * 2/mu1^2 , 2*n_f i x − n1 )
n2_sub <− apply (fz , 1 , min )
n2_sub <− i f e l s e (n2_sub < 10 , 10 , n2_sub )
# t e s t s in s tage I I
delta1_2 <− rnorm (n = m , mean = delta1 , sd = sq r t (2 /n2_sub ) )
Z1_2_sub <− delta1_2 * s q r t (n2_sub/2)
U1_sub <− s q r t ( t ) *Z1_1 + sq r t (1− t ) *Z1_2_sub
# combination o f p−va lue s ( Closed Test ing Procedure )
U01_sub <− s q r t ( t ) *qnorm(1−p01_1) + sq r t (1− t ) *Z1_2_sub
p01_sub <− 1 − pnorm( U01_sub )
i f ( adj == "ClosedTest ing " ) {
sig_sub <− i f e l s e ( p01_sub < alpha/2 & 1 − pnorm(U1_sub ) < alpha/ 2 ,
1 , 0)
}
i f ( adj == "Bonfe r ron i " ) {
sig_sub <− i f e l s e (1 − pnorm(U1_sub ) < alpha/ 4 , 1 , 0)
}
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# i f t o t a l populat ion i s s e l e c t e d
# sample s i z e in s tage I I
br <− (qnorm(1 − alpha/ 4) / sq r t (1− t ) − qnorm( beta_CP ) − s q r t ( t /(1− t ) )
* Z0_1)
br <− i f e l s e (br < 0 , 0 , br )
fz_tot <− cbind (br^2 * 2/mu0^2 , 2*n_f i x − n1 )
n2_tot <− apply (fz_tot , 1 , min )
n2_tot <− i f e l s e (n2_tot < 10 , 10 , n2_tot )
# t e s t s in s tage I I
delta0_2 <− rnorm (n = m , mean = delta0 , sd = sq r t (2 /n2_tot ) )
Z0_2_tot <− delta0_2 * s q r t (n2_tot/ 2)
U0_tot <− s q r t ( t ) *Z0_1 + sq r t (1− t ) *Z0_2_tot
# combination o f p−va lue s ( Closed Test ing Procedure )
U01_tot <− s q r t ( t ) *qnorm(1−p01_1) + sq r t (1− t ) *Z0_2_tot
p01_tot <− 1 − pnorm( U01_tot )
i f ( adj == "ClosedTest ing " ) {
sig_tot <− i f e l s e ( p01_tot < alpha/2 & 1 − pnorm(U0_tot ) < alpha/ 2 ,
1 , 0)
}
i f ( adj == "Bonfe r ron i " ) {
sig_tot <− i f e l s e (1 − pnorm(U0_tot ) < alpha/ 4 , 1 , 0)
}
# i f co−primary ana l y s i s i s s e l e c t e d
# sample s i z e in s tage I I
n2_cop <− cbind ( i f e l s e (n2_tot*p > n2_sub , n2_tot , n2_sub/p ) , 2*n_f i x −
n1 )
n2_cop <− apply (n2_cop , 1 , min )
# t e s t s in s tage I I
Delta_2 <− matrix ( rep (NA , m* 2) , m , 2)
f o r (j in 1 : m ) {
Delta_2 [ j , ] <− mvrnorm (n = 1 , mu = c ( delta0 , delta1 ) , Sigma= matrix (
c (2 /n2_cop [ j ] , 2/n2_cop [ j ] , 2/n2_cop [ j ] , 2/ (n2_cop [ j ] *p ) ) , 2 , 2) )
}
# subgroup
Z1_2 <− Delta_2 [ , 2 ] * s q r t (n2_cop*p/ 2)
p1_2 <− 1 − pnorm(Z1_2)
U1 <− s q r t ( t ) *Z1_1 + sqr t (1− t ) *Z1_2
p1 <− 1 − pnorm(U1 )
# t o t a l populat ion
Z0_2 <− Delta_2 [ , 1 ] * s q r t (n2_cop/ 2)
p0_2 <− 1 − pnorm(Z0_2)
U0 <− s q r t ( t ) *Z0_1 + sqr t (1− t ) *Z0_2
p0 <− 1 − pnorm(U0 )
# combination o f p−va lue s ( Closed Test ing Procedure )
p01_2 = apply ( cbind (2 *apply ( cbind (p0_2 , p1_2) , 1 , min ) , apply ( cbind (p0
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_2 , p1_2) , 1 , max) ) , 1 , min )
U01 = sqr t ( t ) *qnorm(1−p01_1) + sq r t (1− t ) *qnorm(1−p01_2)
i f ( adj == "ClosedTest ing " ) {
sig_cop = i f e l s e ( ( U01 > qnorm(1−alpha/ 2) & U0 > qnorm(1−alpha/ 2) ) |
( U01 > qnorm(1−alpha/ 2) & U1 > qnorm(1−alpha/ 2) ) , 1 , 0)
}
i f ( adj == "Bonfe r ron i " ) {
sig_cop = i f e l s e (p0 < alpha/4 | p1 < alpha/ 4 , 1 , 0)
}
# sample s i z e
n2_v <− i f e l s e ( selSub == 1 , n2_sub , n2_tot )
n2_v <− i f e l s e ( selCop == 1 , n2_cop , n2_v )
n2_v <− round ( i f e l s e ( selFut == 1 , 0 , n2_v ) )
n_v <− round (n1 + n2_v )
# S i gn i f i k an z
sig_a l l <− i f e l s e ( selSub == 1 , sig_sub , sig_tot )
sig_a l l <− i f e l s e ( selCop == 1 , sig_cop , sig_a l l )
sig_a l l <− i f e l s e ( selFut == 1 , 0 , sig_a l l )
poweri <− mean( sig_a l l )
i f ( poweri >= 0 . 8 ) break
}
return ( l i s t ( data . frame ( selSub = selSub , selTot = selTot , selCop = selCop
, selFut = selFut ,
sig_a l l = sig_a l l , n2 = n2_v , n = n_v ) ,
data . frame (p = p , t = t , delta1 = delta1 , delta2 = delta2 , m
= m , c0 = c0 , c1 = c1 ,
beta = beta , alpha = alpha , CP = CP , n_f i x = n_
f ix , conP = 1 − beta_CP , sel_rule = 2) ) )
}
##############################################################
# Function that saves r e s u l t s o f Samples ize_Se l1 / Samples ize_Se l2
# f o r d i f f e r e n t t in a matrix
##############################################################
##############################################################
# Parameters to s p e c i f y :
# same as f o r amples i ze_Se l1 / Samples ize_Sel2 , but :
# t = vecto r o f in te r im ana l y s i s t iming
##############################################################
Samplesize_Sel1_t <− f unc t i on (p , t , delta1 , delta2 , m , c , beta , alpha , CP ,
adj , seed ) {
sim <− as . numeric ( )
f o r (ti in t ) {
sim <− rbind (sim , Samplesize_Sel1 (p , ti , delta1 , delta2 , m , c , beta ,
alpha , CP , adj , seed ) )
}
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sim
}
Samplesize_Sel2_t <− f unc t i on (p , t , delta1 , delta2 , m , c0 , c1 , beta ,
alpha , CP , adj , seed ) {
sim <− as . numeric ( )
f o r (ti in t ) {
sim <− rbind (sim , Samplesize_Sel2 (p , ti , delta1 , delta2 , m , c0 , c1 ,
beta , alpha , CP , adj , seed ) )
}
sim
}
##############################################################
# Function to p l o t sample s i z e d i s t r i b u t i o n ( histogram plus boxplot )
# f o r both s e l e c t i o n r u l e s
##############################################################
##############################################################
# Parameters to s p e c i f y :
# sim = s imu la t i on r e s u l t s r e c e i v ed from func t i on Samples ize_Se l1_t or
# Samples ize_Se l2_t
##############################################################
Plot_Samplesize <− f unc t i on ( sim ) {
simm <− as . numeric ( )
f o r (i in 1 : dim( sim ) [ 1 ] ) {
simm <− rbind (simm , cbind ( sim [ [ i , 1 ] ] , t = sim [ [ i , 2 ] ] $ t ) )
}
sel_rule <− sim [ [ 1 , 2 ] ] $sel_rule
i f ( sel_rule == 1) {
selection <− as . f a c t o r ( simm$selSub )
selection <− r e l e v e l ( selection , "1" )
c o l <− brewer . pal (5 , " Set1 " ) [ 1 : 2 ]
}
i f ( sel_rule == 2) {
selection <− rep (0 , dim( simm ) [ 1 ] )
selection <− i f e l s e ( simm$selSub == 1 , 1 , selection )
selection <− i f e l s e ( simm$selTot == 1 , 2 , selection )
selection <− i f e l s e ( simm$selCop == 1 , 3 , selection )
selection <− as . f a c t o r ( selection )
c o l <− brewer . pal (5 , " Set1 " )
col2 <− brewer . pal (6 , " Set2 " )
c o l <− c ( col2 [ 6 ] , c o l [ 1 : 3 ] )
}
n_f i x <− as . numeric ( sim [ [ 1 , 2 ] ] [ "n_f i x " ] )
m <− sim [ [ 1 , 2 ] ] $m
P <− ggplot (simm , aes (x = simm$n , fill = selection ) ) +
geom_histogram ( position = " stack " , binwidth = round (n_f i x / 100) * 2 ,
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alpha = 0 . 7 ) +
facet_gr id ( simm$ t ~ . , scales = " f r e e " ) +
xlab ( "n" ) +
ylab ( "" ) +
theme_bw ( ) +
s c a l e_y_continuous ( breaks = NULL ) +
theme ( l egend . position = "none" , t ex t = element_text ( size = 25) ) +
s c a l e_fill_manual ( values = co l )
# draw boxplot
means <− as . numeric ( )
medians <− as . numeric ( )
b <− boxplot ( simm$n ~ simm$t , p l o t = FALSE )
box_s t a t <− b$stats
mh <− as . numeric ( )
wu <− as . numeric ( )
wo <− as . numeric ( )
bu <− as . numeric ( )
bo <− as . numeric ( )
bb <− as . numeric ( )
m_middle <− as . numeric ( )
m_up <− as . numeric ( )
m_low <− as . numeric ( )
r <− 0 .3 # width o f the boxplot in r e l a t i o n to p l o t h ight
panel <− 0
f o r (k in l e v e l s ( as . f a c t o r ( simm$ t ) ) ) {
panel <− panel + 1
# mean
me <− rep (mean( simm$n [ which ( simm$ t == k ) ] ) , m )
means <− c ( means , me )
# median
md <− rep (median ( simm$n [ which ( simm$ t == k ) ] ) , m )
medians <− c ( medians , md )
# box width
maxh <− max( ggplot_build (P ) $data [ [ 1 ] ] $ymax [ ggplot_build (P ) $data [ [ 1 ] ] $
PANEL == panel ] )
mh_ <− rep ( maxh*r , m )
mh_[ 1 ] <− maxh*(1−r )
mh <− c (mh , mh_)
# middle o f box
m_middle_ <− rep ( maxh * 0 . 5 , m )
m_middle <− c (m_middle , m_middle_)
# upper and lower end o f box
m_up_ <− rep ( maxh * (1−r ) , m )
m_up <− c (m_up , m_up_)
m_low_ <− rep ( maxh * r , m )
m_low <− c (m_low , m_low_)
# whisker
wu_ <− box_s t a t [ 1 , panel ]
wu_ <− rep (wu_, m )
wu_[ 1 ] <− box_s t a t [ 2 , panel ]
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wu <− c (wu , wu_)
wo_ <− box_s t a t [ 4 , panel ]
wo_ <− rep (wo_, m )
wo_[ 1 ] <− box_s t a t [ 5 , panel ]
wo <− c (wo , wo_)
# box he ight
bb_ <− box_s t a t [ 2 , panel ]
bb_ <− rep (bb_, m )
bb_[ 1 ] <− box_s t a t [ 4 , panel ]
bb <− c (bb , bb_)
# box ( f i r s t and th i rd q u a r t i l e )
bu_ <− rep ( box_s t a t [ 2 , panel ] , m )
bu <− c (bu , bu_)
bo_ <− rep ( box_s t a t [ 4 , panel ] , m )
bo <− c (bo , bo_)
}
P <− P + geom_point ( aes (x=means , y = m_middle ) , size = 2 , shape = 19) +
geom_line ( aes (x = medians , y = mh ) , size = 1 . 5 ) +
geom_line ( aes (x = wu , y = m_middle ) , size = 1 , lineend = " square " ) +
geom_line ( aes (x = wo , y = m_middle ) , size = 1 , lineend = " square " ) +
geom_line ( aes (x = bb , y = m_up ) , size = 1 , lineend = " square " ) +
geom_line ( aes (x = bb , y = m_low ) , size = 1 , lineend = " square " ) +
geom_line ( aes (x = bu , y = mh ) , size = 1 , lineend = " square " ) +
geom_line ( aes (x = bo , y = mh ) , size = 1 , lineend = " square " )
p l o t (P )
}
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